[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 391
1. Maes L, Kalala JP, Cornelissen M, De Ridder L: PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo; 2006 Mar-Apr;20(2):271-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCNA, Ki-67 and hTERT in residual benign meningiomas.
  • BACKGROUND: Relapse in individual patients after incomplete/residual removal of meningiomas cannot be predicted by histology alone as re-growth occurs even in histologically benign meningiomas.
  • MATERIALS AND METHODS: Proliferating cell nuclear antigen (PCNA), Ki-67 and human telomerase reverse transcriptase (hTERT) labelling indices were measured in histological sections derived from residual meningiomas in 37 patients to assess their relationship to relapse.
  • The histological specimens comprised the following 2 groups: (i) stable for at least 10 years after initial partial resection of residual meningiomas: 20 specimens;.
  • (ii) relapsing between 11 and 145 months after initial resection of residual meningiomas: 17 specimens.
  • CONCLUSION: The mean PCNA, Ki-67 and hTERT LI were higher in the relapsing group of residual meningiomas than in the stable group, although no statistical difference was found for PCNA and Ki-67.
  • On the other hand, a statistical difference between the two groups of meningiomas was found for hTERT; however, it is no absolute predictor for relapse at the individual patient level.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Telomerase / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634530.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


2. Roser F, Nakamura M, Ritz R, Bellinzona M, Dietz K, Samii M, Tatagiba MS: Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer; 2005 Aug 1;104(3):598-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
  • BACKGROUND: Some authors have suggested that the biology of meningiomas differs according to a patient's age.
  • Proliferation, vascularity, and hormonal status in meningiomas can be used to describe changes during aging.
  • In the current study, proliferation activity with the Ki-67/MIB-1 antibody was evaluated by immunohistochemistry in meningioma tissue specimens from young and elderly patients.
  • METHODS: Over the past 25 years, tissue samples from 1766 patients with meningiomas were evaluated.
  • Of these, 588 tumor specimens from 554 patients who underwent surgery between 1990 and 2000 were evaluated immunohistochemically.
  • The proliferation index (LI) and progesterone receptor (PR) in meningiomas were quantitatively estimated in elderly (age > or = 70 years) and young patients (age < 70 years).
  • Correlations with histologic subtype, disease recurrence-free survival, resection grade, location, size, vascularity, and tumor calcification were calculated as well.
  • RESULTS: Compared with the young group of 344 patients with meningioma (age < 70 years; mean age, 51.9 years; range, 18-69 years), the elderly population (age > or = 70 years; n = 41; mean age, 74.9 years; range, 70-88 years) showed a male-to-female ratio of 3.2: 1.
  • CONCLUSIONS: Proliferation rates and PR status in benign intracranial meningiomas did not appear to be age dependent.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Proliferation. Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15952201.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / Receptors, Progesterone
  •  go-up   go-down


3. Monleón D, Morales JM, Gonzalez-Segura A, Gonzalez-Darder JM, Gil-Benso R, Cerdá-Nicolás M, López-Ginés C: Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res; 2010 Nov 1;70(21):8426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic aggressiveness in benign meningiomas with chromosomal instabilities.
  • Meningiomas are often considered benign tumors curable by surgery, but most recurrent meningiomas correspond to histologic benign tumors.
  • The aim of this study was to achieve higher specificity in the detection of meningioma subgroups by measuring chromosomal instabilities by fluorescence in situ hybridization and cytogenetics and metabolic phenotypes by high-resolution magic angle spinning spectroscopy.
  • We studied 46 meningioma biopsies with these methodologies.
  • Of these, 34 were of WHO grade 1 and 12 were of WHO grade 2.
  • Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities.
  • The metabolic phenotype of this subgroup indicated an aggressive metabolism resembling that observed for atypical meningioma.
  • Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors.
  • Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.
  • [MeSH-major] Chromosomal Instability. Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Metabolome / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861191.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • Supervised classification of the tumors did not reveal specific expression patterns representative of each WHO grade.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • Taken together, our microarray-based expression profiling revealed interesting novel candidate genes and pathways that may contribute to meningioma progression.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery; 2009 Feb;64(2 Suppl):A7-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients.
  • OBJECTIVE: To present initial, short-term results obtained with an image-guided radiosurgery apparatus (CyberKnife; Accuray, Inc., Sunnyvale, CA) in a series of 199 benign intracranial meningiomas.
  • CONCLUSION: The introduction of the CyberKnife extended the indication to 63 patients (>30%) who could not have been treated by single-session radiosurgical techniques.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165077.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Nagar VA, Ye JR, Ng WH, Chan YH, Hui F, Lee CK, Lim CC: Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation. AJNR Am J Neuroradiol; 2008 Jun;29(6):1147-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging: diagnosing atypical or malignant meningiomas and detecting tumor dedifferentiation.
  • BACKGROUND AND PURPOSE: Atypical and malignant meningiomas are uncommon tumors with aggressive behavior and higher mortality, morbidity, and recurrence compared with benign tumors.
  • We investigated the utility of diffusion-weighted (DW) MR imaging to differentiate atypical/malignant from benign meningiomas and to detect histologic dedifferentiation to higher tumor grade.
  • MATERIALS AND METHODS: We retrospectively compared conventional and DW MR images (b-value 1000 s/mm(2)) acquired on a 1.5T clinical scanner between 25 atypical/malignant and 23 benign meningiomas.
  • RESULTS: Irregular tumor margins, peritumoral edema, and adjacent bone destruction occurred significantly more often in atypical/malignant than in benign meningiomas.
  • The mean ADC of atypical/malignant meningiomas (0.66 +/- 0.13 x 10(-3) mm(2)/s) was significantly lower compared with benign meningiomas (0.88 +/- 0.08 x 10(-3) mm(2)/s; P < .0001).
  • Mean NADC ratio in the atypical/malignant group (0.91 +/- 0.18) was also significantly lower than the benign group (1.28 +/- 0.11; P < .0001), without overlap between groups.
  • Two patients had isointense benign tumors on initial DW MR imaging, and these became hyperintense with the decrease in ADC and NADC below these thresholds when they progressed to atypical and malignant meningiomas on recurrence.
  • CONCLUSIONS: ADC and NADC ratios in atypical/malignant meningiomas are significantly lower than in benign tumors.
  • Decrease in ADC and NADC on follow-up imaging may suggest dedifferentiation to higher tumor grade.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2009 Feb;30(2):E21 [19193747.001]
  • (PMID = 18356472.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Zada G, Pagnini PG, Yu C, Erickson KT, Hirschbein J, Zelman V, Apuzzo ML: Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas. Neurosurgery; 2010 Aug;67(2):322-8; discussion 328-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas.
  • OBJECT: To characterize the timing and patterns of long-term treatment failure after Gamma Knife radiosurgery (GKRS) for benign meningiomas.
  • METHODS: Data were retrospectively reviewed in 116 patients who underwent 136 GKRS treatments for benign intracranial meningiomas from 1996 to 2004.
  • Patients with atypical or malignant meningiomas were excluded.
  • CONCLUSIONS: GKRS demonstrates excellent long-term tumor control in the management of benign meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644417.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, Patro S, Saini J, George U, Sarma PS: Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol; 2010 Dec;37(5):277-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion tensor imaging in differentiating subtypes of meningiomas.
  • PURPOSE: Meningiomas are the most common extraaxial intracranial type of tumor, and their management and prognosis depend on their grade and histology.
  • The aim of the present study was to assess the role of diffusion and diffusion tensor metrics in the identification and classification of meningioma grades and subtypes.
  • METHODS AND MATERIALS: A total of 21 consecutive patients with meningioma were included in this retrospective study, of whom 16 had benign meningiomas (three fibroblastic, 11 transitional/mixed, two meningothelial) and five had atypical meningiomas.
  • Tumor mean diffusivity (Dav), fractional anisotropy (FA), linear anisotropy (CL), planar anisotropy (CP), spherical anisotropy (CS) and eigenvalues (e1, e2, e3) were measured in all cases, and differences in diffusion tensor metrics between atypical, fibroblastic and other benign (transitional, meningothelial) meningiomas were statistically analyzed using the Mann-Whitney test.
  • RESULTS: No statistically significant differences were found among the mean Dav values for atypical, fibroblastic and other benign meningiomas.
  • Both atypical and fibroblastic meningiomas showed significantly higher mean FA values and lower mean CS values compared with other meningiomas (P<0.01), but no statistically significant difference in these values between each other.
  • Atypical meningiomas showed higher CL values compared with fibroblastic and other benign meningiomas but, again, the difference was not statistically significant.
  • Both atypical and fibroblastic meningiomas showed statistically significantly higher CP values and lower e3 values compared with transitional meningiomas (P<0.01).
  • CONCLUSION: These results suggest that diffusion tensor metrics may be helpful in the differentiation of atypical, fibroblastic and other benign meningiomas.
  • [MeSH-major] Diffusion Tensor Imaging. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20381865.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Davidson L, Fishback D, Russin JJ, Weiss MH, Yu C, Pagnini PG, Zelman V, Apuzzo ML, Giannotta SL: Postoperative Gamma Knife surgery for benign meningiomas of the cranial base. Neurosurg Focus; 2007;23(4):E6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative Gamma Knife surgery for benign meningiomas of the cranial base.
  • OBJECT: The standard treatment for meningiomas is complete resection, but the proximity of skull base meningiomas to important neurovascular structures makes complete excision of the lesion difficult or impossible.
  • The authors analyzed the mid- and long-term results obtained in patients treated with postresection Gamma Knife surgery (GKS) for residual or recurrent benign meningiomas of the cranial base.
  • METHODS: Thirty-six patients with residual or recurrent benign meningiomas of the skull base following one or more surgical procedures underwent GKS.
  • It should be initially considered along with surgery for the treatment of complex skull base meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961043.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • BACKGROUND: Approximately 60% of meningiomas are associated with peritumoral edema.
  • The objective of this study was to investigate the correlation of PTBE with clinical, radiologic, and surgical aspects and recurrence of meningiomas.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Meningiomas with larger edema sizes also showed correlation with large meningiomas (P = .035), and the ones with smaller edema sizes correlated with the tentorial location (P = .032).
  • Multivariate analysis showed an association between PTBE and the presence of seizures (odds ratio, 3.469), large meningiomas (odds ratio, 15.977), and for each cubic centimeter added to its size, the risk of edema increased 1.082 times (odds ratio).
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • As a consequence, it is reasonable to consider the presence of edema as an additional factor to be taken into account when mapping out strategies for the treatment of meningiomas.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102(s_supplement):134-139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst formation following gamma knife surgery for intracranial meningioma.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306456.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cyst / gamma knife surgery / meningioma
  •  go-up   go-down


12. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS, Kim JH, Kim CJ, Kwun BD, Lee JK: Visual changes after gamma knife surgery for optic nerve tumors. J Neurosurg; 2005 Jan;102(s_supplement):143-146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ✓ Tumors involving the optic nerve (optic glioma, optic nerve sheath meningioma) are benign but difficult to treat.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306473.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / optic glioma / optic nerve sheath meningioma
  •  go-up   go-down


13. Nakasu S, Fukami T, Jito J, Nozaki K: Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol; 2009;26(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and regrowth of benign meningiomas.
  • The World Health Organization (WHO) grading system for meningioma is helpful for predicting aggressive subtypes.
  • However, even benign meningiomas sometimes show relatively rapid growth and may recur after total removal.
  • We attempted to find histopathological features that would be valuable for predicting recurrence or regrowth of WHO grade I meningiomas.
  • We investigated 135 benign meningiomas, of which 120 were totally removed (Simpson's grade I-III).
  • On the other hand, the histological features of sheet-like growth, prominent nucleoli, and necrosis did not correlate with recurrence, because they were relatively rare in grade I tumors.
  • MIB-1 index and Simpson's grade significantly correlated with retreatment in both univariate and multivariate analyses.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856217.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • OBJECT: The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets.
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas.
  • METHODS: One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4).
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • The PCR analysis demonstrated no changes in eicosanoid expression among meningiomas of different World Health Organization grades and in normal human cortical and dura mater tissue.
  • CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.
  • This finding of the ubiquitous presence of these enzymes in meningiomas offers an excellent baseline for testing upcoming chemotherapeutic treatments.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


15. Kärjä V, Alafuzoff I: Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy. Clin Neuropathol; 2006 Jan-Feb;25(1):37-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy.
  • Dysfunction of ubiquitin system leads to presence of p53 in cells suggested to be a predictor of future recurrence of meningioma.
  • MATERIAL: The study material included 45 benign meningiomas of postmenopausal women operated in Kuopio University Hospital between 1994 and 2002.
  • METHODS: Patterns of p62 immunopositivity in meningiomas was evaluated and the results were correlated to clinical and histological parameters.
  • CONCLUSION: Our results indicate that in the benign not recurrent meningiomas, signs of functioning proteosomal system, can be detected using the p62 labeling.
  • The function of proteosomal system in malignant and specifically invasive meningiomas needs to be further elucidated.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Biomarkers, Tumor / analysis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465773.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / SQSTM1 protein, human
  •  go-up   go-down


16. Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P: Cyberknife Radiosurgery for Benign Meningiomas: Short-term Results in 199 Patients. Neurosurgery; 2009 Feb 01;64(suppl_2):A7-A13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife Radiosurgery for Benign Meningiomas: Short-term Results in 199 Patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28173326.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Haselsberger K, Maier T, Dominikus K, Holl E, Kurschel S, Ofner-Kopeinig P, Unger F: Staged gamma knife radiosurgery for large critically located benign meningiomas: evaluation of a series comprising 20 patients. J Neurol Neurosurg Psychiatry; 2009 Oct;80(10):1172-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staged gamma knife radiosurgery for large critically located benign meningiomas: evaluation of a series comprising 20 patients.
  • OBJECTIVES: This study investigated the efficacy of staged radiosurgical treatment for intracranial meningiomas exceeding 3 cm in diameter.
  • METHODS: Between April 1992 and May 2008, staged gamma knife radiosurgery was performed in 20 patients with large benign meningiomas.
  • CONCLUSION: As a result of excellent tumour control at a low concomitant morbidity, staged radiosurgical treatment for meningiomas represents a safe treatment modality that can be recommended for meningiomas in critical locations either after incomplete surgery or as primary treatment for patients with significant comorbidity.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762911.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Linskey ME, Davis SA, Ratanatharathorn V: Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities. J Neurosurg; 2005 Jan;102(s_supplement):59-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities.
  • OBJECT: The authors sought to assess the respective roles of microsurgery and gamma knife surgery (GKS) in the treatment of patients with meningiomas.
  • METHODS: The authors culled from a 4-year prospective database data on 74 cases of meningiomas.
  • Simpson Grade 1 or 2 resection was achieved in 86.1% of patients who underwent microsurgery.
  • Patients who underwent GKS received a mean margin dose of 16.4 Gy (range 14-20 Gy).
  • In patients with benign meningiomas GKS tumor control was 96.8% with one recurrence at the margin.
  • The recurrence rate was zero of 27 for Simpson Grade 1 or 2 resection and three of four for higher grades in those patients who underwent microsurgery.
  • Symptoms improved in 48.4% of patients undergoing microsurgery and 16.7% of those who underwent GKS.
  • CONCLUSIONS: Both GKS and microsurgery serve important roles in the overall management of patients with meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306454.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gamma knife surgery / meningioma / microsurgery / skull base surgery / stereotaxy
  •  go-up   go-down


19. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
  • Meningiomas are, in general, slowly growing benign tumors attached to the dura mater and composed of neoplastic meningothelial (arachnoidal) cells.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • As invasion of normal tissue may occur in all grades, independent biological markers are needed to identify the more aggressive and recurrent meningiomas.
  • The lysosomal cysteine proteinases, cathepsins B and L, have been associated with tumor invasiveness and the aim of this study was therefore to evaluate them, together with their endogenous inhibitors stefin B and cystatin C, as potential markers for the aggressiveness of meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The protein levels of cathepsins B (p=0.050) and L (p=0.019) were found to be significantly higher in atypical than in benign meningiomas.
  • Protein and mRNA levels of stefin B (p= 0.007), but not cystatin C, were significantly lower in atypical compared with benign meningiomas.
  • The expression of cathepsins and inhibitors was not different between central and peripheral meningioma tissue or between histological subtypes of meningiomas, with the exception of cathepsin L, the level of which was significantly lower in transitional meningiomas.
  • We conclude that higher protein levels of cathepsins B and L and lower mRNA levels of stefin B are potential diagnostic markers for invasive and aggressive behavior of meningiomas.
  • The diagnostic and prognostic value for relapse of meningioma needs to be confirmed in a larger population of patients.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


20. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol; 2009 May 20;27(15_suppl):2062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas.
  • : 2062 Background: No effective treatment is available for recurrent meningiomas when surgical and radiation options are exhausted.
  • The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth.
  • In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients.
  • METHODS: Patients with recurrent histologically confirmed meningiomas and no more than two previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity.
  • Eight patients (32%) had benign tumors, 9 (36%) atypical, and eight (32%) malignant.
  • For benign tumors, the 6-month progression-free survival (PFS6) was 29%, 12-month PFS (PFS12) 0%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%.
  • CONCLUSIONS: Neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.
  • The role of EGFR inhibitors in meningiomas is unclear but evaluation of EGFR inhibitors in combination with other targeted molecular agents may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas.
  • Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II).
  • Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001).
  • We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


22. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery; 2007 Nov;61(5):1048-59; discussion 1060-1
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?
  • OBJECTIVE: Although histologically benign, Grade I meningiomas can sometimes behave aggressively.
  • The clinically-aggressive subset of Grade I meningiomas is typically indistinguishable from clinically-benign Grade I meningiomas in vivo.
  • We compared molecular genetic and biochemical findings to clinical, pathological, and immunohistochemical information in a series of clinically-aggressive Grade I meningiomas with a series of clinically-benign meningiomas to identify characteristics that may be used to distinguish between these two groups.
  • METHODS: Tumor tissue samples from 30 patients with Grade I meningiomas were harvested.
  • RESULTS: Molecular genetic and biochemical findings correlated with clinical behavior of the two Grade I meningioma groups.
  • The presence of aberrations also influenced meningioma regrowth after subtotal resection.
  • Alanine was decreased in meningiomas with chromosomal aberrations in tumors that recurred.
  • CONCLUSION: Distinct molecular genetic and biochemical alterations differentiated clinically-aggressive Grade I meningiomas from clinically-benign Grade I meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Spectroscopy / methods. Meningioma / diagnosis. Meningioma / physiopathology. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091281.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protons
  •  go-up   go-down


23. Swinnen LJ, Rankin C, Rushing EJ, Laura HF, Damek DM, Barger GR: Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). J Clin Oncol; 2009 May 20;27(15_suppl):2063

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811).
  • : 2063 Background: Meningiomas account for 15%-18% of CNS tumors.
  • Although benign, recurrence is seen in 16%-39% of cases, depending on the extent of resection possible.
  • Induction of apoptosis was furthermore demonstrated with HU in primary benign meningioma explant cultures.
  • The S9811 phase II trial was undertaken to estimate the objective response rate, if any, of unresectable benign meningioma to this HU regimen.
  • METHODS: Eligibility required unresectable, measurable, residual or recurrent, histologically-proven benign meningioma.
  • Toxicity was mainly hematologic: 11/28 (39%) grade 3, 2/28 (11%) grade 4.
  • Grade 3 non-hematologic toxicity was seen in 7/28 (25%).
  • CONCLUSIONS: Chronic HU therapy for unresectable benign meningioma resulted in an estimated objective response rate of < 12%.
  • Whether the stable disease rate seen differs in any way from what can be expected from the natural history of meningioma cannot be determined from this phase II study design.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ren G, Chen S, Wang Y, Zhu RJ, Geng DY, Feng XY: Quantitative evaluation of benign meningioma and hemangiopericytoma with peritumoral brain edema by 64-slice CT perfusion imaging. Chin Med J (Engl); 2010 Aug 5;123(15):2038-44
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative evaluation of benign meningioma and hemangiopericytoma with peritumoral brain edema by 64-slice CT perfusion imaging.
  • BACKGROUND: Hemangiopericytomas (HPCs) have a relentless tendency for local recurrence and metastases, differentiating between benign meningiomas and HPCs before surgery is important for both treatment planning and the prognosis appraisal.
  • The purpose of this study was to evaluate the correlations between CT perfusion parameters and microvessel density (MVD) in extra-axial tumors and the possible role of CT perfusion imaging in preoperatively differentiating benign meningiomas and HPCs.
  • METHODS: Seventeen patients with benign meningiomas and peritumoral edema, 12 patients with HPCs and peritumoral edema underwent 64-slice CT perfusion imaging pre-operation.
  • The quantitative parameters, include cerebral blood volume (CBV), permeability surface (PS) of parenchyma, peritumoral edema among benign meningiomas and HPCs were compared respectively.
  • CBV and PS in parenchyma, peritumoral edema of benign meningiomas and HPCs were also compared to that of the contrallateral normal white matter respectively.
  • RESULTS: The value of CBV and PS in parenchyma of HPCs were significantly higher than that of benign meningiomas (P < 0.05), while the values of CBV and PS in peritumoral edema of benign meningiomas and HPCs were not significantly different (P > 0.05).
  • MVD in parenchyma of HPCs were significantly higher than that of benign meningiomas (P < 0.05).
  • Furthermore, the value of CBV and PS in parenchyma of benign meningiomas and HPCs were significantly higher than that of contrallateral normal white matter (P < 0.05), the value of CBV in peritumoral edema of benign meningiomas and HPCs were significantly lower than that of contrallateral normal white matter (P < 0.05), while the value of PS in peritumoral edema of benign meningiomas and HPCs were not significantly different with that of contrallateral normal white matter (P > 0.05).
  • CONCLUSIONS: CT perfusion imaging can provide critical information on the vascularity of HPC and benign meningiomas.
  • Determination of maximal CBV and corresponding PS values in the parenchyma may be useful in the preoperative differentiating HPC from benign meningiomas.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Meningioma / diagnosis. Tomography, X-Ray Computed / methods


25. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Stereotactic radiosurgery has been used as an alternative or adjuvant therapy to surgery for meningiomas in locations, such as the skull base, where operative manipulation may be particularly difficult.
  • Stereotactic radiotherapy is useful for larger meningiomas (> 3-3.5 cm) and those closely approximating critical structures, such as the optic chiasm and brainstem.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • Stereotactic radiotherapy has toxicity equivalent to that of radiosurgery, despite its biased use for larger meningiomas with more complicated volumes.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


26. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • Meningiomas of WHO grade I can usually be cured by surgical resection.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts.
  • In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • Comparing the protein spectra from invasive and noninvasive fibrous meningioma we found 22 peaks whose intensities were significantly different between the two groups (P < 0.001).
  • In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • A possibility for early identification of invasive grade I meningiomas may have a strong influence on the follow-up policy and the issue of early or late radiotherapy.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol; 2009 Mar;92(1):1-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
  • Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal.
  • Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases.
  • Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed.
  • Antiprogesterone treatment can also be considered in recurrent benign meningiomas.
  • Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Meningeal Neoplasms / therapy. Meningioma / therapy. Neoplasm Recurrence, Local / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023520.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 43
  •  go-up   go-down


28. Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology; 2007 Oct;27(5):407-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
  • Histological analysis has limited value to predict biological behavior of meningiomas.
  • We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas.
  • We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied.
  • There was no dependable histological parameter to predict recurrence among benign-looking meningiomas.
  • The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas.
  • In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339).
  • Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas.
  • MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.
  • [MeSH-major] Biomarkers / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018472.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


29. Goldsmith B, McDermott MW: Meningioma. Neurosurg Clin N Am; 2006 Apr;17(2):111-20, vi
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma.
  • Total excision is an appropriate treatment option for patients with benign meningiomas that are resectable with minimal morbidity.
  • Fractionated conformal radiotherapy is an appropriate primary treatment option for patients with benign meningiomas of all sizes and all sites.
  • It is particularly appropriate and preferred for optic nerve sheath meningiomas, for which there are few alternatives.
  • [MeSH-major] Meningeal Neoplasms. Meningioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793503.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


30. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE: Radiosurgery for large-volume (&gt; 10 cm3) benign meningiomas. J Neurosurg; 2010 May;112(5):951-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for large-volume (> 10 cm3) benign meningiomas.
  • OBJECT: Stereotactic radiosurgery (SRS) has proven to be a safe and effective treatment for many patients with intracranial meningiomas.
  • Nevertheless, the morbidity associated with radiosurgery of larger meningiomas is poorly understood.
  • METHODS: The authors performed a retrospective review of 116 patients who underwent SRS for meningiomas (WHO Grade I) > 10 cm3 between 1990 and 2007, with a minimum follow-up of 12 months.
  • Patients with atypical or malignant meningiomas and those who received prior radiotherapy were excluded.
  • CONCLUSIONS: The morbidity associated with SRS for patients with benign meningiomas > 10 cm(3) is greater for supratentorial tumors compared with skull base tumors.
  • Whereas radiosurgery is relatively safe for patients with large-volume skull base meningiomas, resection should remain the primary disease management for the majority of patients with large-volume supratentorial meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Dec;113(6):1335-6; author reply 1336-7 [20887089.001]
  • (PMID = 19764829.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Murakami M, Imahori Y, Kimura S, Tatsuzawa K, Ohwada K, Inoue Y, Sasajima H, Mineura K: Positron emission tomography elucidates transport system and tumor proliferation in meningiomas. Oncol Rep; 2005 Oct;14(4):853-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography elucidates transport system and tumor proliferation in meningiomas.
  • To test the in vivo transport system and tumor proliferation of meningiomas, in comparison with gliomas, 25 patients with meningiomas and 8 gliomas underwent quantitative kinetic analysis of ([18F])fluoro-2-deoxy-D-glucose (FDG) - positron emission tomography (PET) imaging and immunohistochemical study.
  • K1 was higher in meningiomas than in gliomas and was higher in atypical than in benign meningiomas. k3 was correlated with MIB-1 LI in meningiomas, but not in gliomas.
  • Immunohistochemically, meningiomas were less reactive to VEGF or Glut-1 than gliomas but atypical meningiomas stained more intensely than benign meningiomas.
  • The vascular surface area was significantly larger in meningiomas than in gliomas and atypical meningiomas had high values for both permeability and surface area than benign meningiomas.
  • High values for K1 and k3 indicate the aggressive proliferation of meningiomas and, in atypical meningiomas, the synergistic interaction of the high permeability and the large surface area yielded conditions conducive to glucose metabolism and tumor proliferation.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasms / pathology. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142342.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor
  •  go-up   go-down


32. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The study population included 10,834 individuals who were treated for tinea capitis with X rays in the 1950s and two matched nonirradiated groups, comprising population and sibling comparison groups.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.


33. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • Atypical and malignant meningiomas are more likely to recur than benign meningiomas.
  • We aimed to distinguish atypical and malignant meningiomas from benign meningiomas based on imaging findings.
  • Between 2004 and 2007, a total of 75 patients with resected intracranial meningiomas were retrospectively reviewed.
  • Histopathological grades were assigned as benign and atypical/malignant meningiomas according to the World Health Organization (WHO) classification.
  • There were 59 benign and 16 atypical/malignant meningiomas.
  • Only intratumoral cystic change and extracranial tumor extension through the skull base foramina were more prevalent in atypical/malignant meningiomas (p=0.001).
  • Hence, these two imaging features might be potential markers of atypical/malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


34. Modha A, Gutin PH: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery; 2005 Sep;57(3):538-50; discussion 538-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
  • Atypical and anaplastic meningiomas are uncommon tumors with a poorer prognosis than benign meningiomas.
  • Both tumors are rare and are often integrated with benign meningiomas when treatments are evaluated.
  • In addition, because there has not been one histopathological classification scheme for atypical and anaplastic meningiomas in the past, there are numerous inconsistencies in the literature.
  • Malignant progression with accumulation of mutations in a benign meningioma can result in an atypical and/or anaplastic meningioma.
  • The extent of tumor resection and histological grade are the key determinants for recurrence.
  • [MeSH-major] Brain Neoplasms / therapy. Meningeal Neoplasms / therapy. Meningioma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145534.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Number-of-references] 65
  •  go-up   go-down


35. Hernández Faraco A, Céspedes G, Trejo E: [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. Neurologia; 2009 May;24(4):235-44
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas].
  • [Transliterated title] Expresión inmunohistoquímica del receptor de progesterona en relación con el grado histológico y riesgo de recidivas en meningiomas intracraneanos.
  • INTRODUCTION: Meningiomas are frequent primary neoplasms of the central nervous system, usually benign and susceptible to healing through surgery.
  • The histological grade of the WHO and the extension of the initial surgical resection are determining prognostic factors in these tumors.
  • Nevertheless, a recurrence rate close to 20 % in benign meningiomas completely diseccated arises the need of considering new prognostic factors.
  • METHODS: A total of 93 cases were selected for the immunohistochemical study of the progesterone receptor (PR) in relation to the histological grade and the risk of recurrencies in meningiomas.
  • RESULTS: Though the immunohistochemical labelling index (LI) of the PR decreased with the progression of the histological grade (means of 27.37 % for grade I, 17.89% for grade II, and 13.50% for grade III), such correlation was not statistically significant and the cut off estimated in 20% was not satisfactory to discriminate among benign meningiomas (grade I) and non benign (grades II-III) due to its poor sensitivity (56.10%) and positive predictive value (56.10 %).
  • The comparison of the LI of the PR among non recurrent meningiomas (36.35 %) and recurrent (22.10%) was neither statistically significant, but permitted to establish a useful cut off of 40% (LI >40% in 13/23 non recurrent tumors and <40% in 19/23 recurrent tumors) with a sensitivity of 82.61% and a positive predictive value of 65.52%.
  • CONCLUSION: The LI of the PR is apparently not related to the histological grade of the meningiomas, but is significantly smaller in recurrent meningiomas.
  • A meningioma with a LI of the PR less than 40 % suggests the risk of recurrences.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptors, Progesterone / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603293.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone
  •  go-up   go-down


36. Maes L, Kalala JP, Cornelissen M, de Ridder L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif; 2007 Feb;40(1):14-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of astrocytomas and meningiomas: an evaluation in vitro.
  • By verifying the proliferation capacity, human telomerase reverse transcriptase (hTERT) expression and in vitro invasion, in a group of highly malignant glioblastomas, benign meningiomas and astrocytomas, at the initial stage of progression, we have analysed putative progression in vitro for proliferation and telomerase expression.
  • MATERIALS AND METHODS: The relative proliferation status (visualized with Ki-67 antibodies) and presence of hTERT protein was analysed in 27 intracranial tumours (6 astrocytomas, 8 glioblastomas and 13 meningiomas) by immunohistochemistry on paraffin-embedded biopsy tissue, as well as on primary tumour-derived cell cultures.
  • RESULTS: The mean proliferation indices were 22.3 (SD = 18.1) for glioblastomas and 2.1 (SD = 1.9) for low-grade (LG) astrocytomas.
  • The group of benign meningiomas had a labelling index of 2.2 (SD = 2.7).
  • The group of benign meningiomas had a labelling index of 12.4 (SD = 19.2) for hTERT.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227292.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


37. Minniti G, Amichetti M, Enrici RM: Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol; 2009;4:42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and radiosurgery for benign skull base meningiomas.
  • Meningiomas located in the region of the base of skull are difficult to access.
  • Local control following subtotal excision of benign meningiomas can be improved with conventional fractionated external beam radiation therapy with a reported 5-year progression-free survival up to 95%.
  • Fractionated RT delivered as FSRT, IMRT and protons is useful for larger and irregularly or complex-shaped skull base meningiomas close to critical structures not suitable for single-fraction SRS.
  • Because of the long natural history of benign meningiomas, larger series and longer follow-up are necessary to compare results and toxicity of different techniques.
  • [MeSH-major] Meningioma / radiotherapy. Meningioma / surgery. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22 [16029801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1427-31 [16029803.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1425-30 [16170090.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5):873-86; discussion 873-86 [16284558.001]
  • [Cites] Technol Cancer Res Treat. 2005 Dec;4(6):675-82 [16292888.001]
  • [Cites] Surg Neurol. 2006 Jan;65(1):28-33; discussion 33-4 [16378847.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):28-36; discussion 28-36 [16385326.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 May;64(5):542-8 [16649974.001]
  • [Cites] Radiat Oncol. 2006;1:46 [17173702.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):90-5 [17161483.001]
  • [Cites] Neurosurgery. 2006 Dec;59(6):1188-94; discussion 1194 [17277681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] J Neurosurg. 2007 Aug;107(2):325-36 [17695387.001]
  • [Cites] Neurosurgery. 2007 Aug;61(2):281-6; discussion 286-7 [17762740.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):745-51 [17937218.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:68-73 [11143266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):285-94; discussion 294-6 [11220370.001]
  • [Cites] J Neurosurg. 2001 May;94(5):816-21 [11354416.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):325-31 [11483185.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):435-9 [11565865.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):710-3 [11596968.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Acta Neurochir (Wien). 2001 Nov;143(11):1141-52 [11731865.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E6 [17961043.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):937-44 [17977264.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Prog Neurol Surg. 2009;22:96-111 [18948722.001]
  • [Cites] Can J Neurol Sci. 2002 Aug;29(3):240-8 [12195613.001]
  • [Cites] Acta Neurochir Suppl. 2002;84:71-6 [12379007.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1373-79; discussion 1379-80 [12445342.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1473-82 [14508835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1375-83; discussion 1383-4 [15157294.001]
  • [Cites] Radiother Oncol. 2004 Jun;71(3):251-8 [15172139.001]
  • [Cites] Neurosurgery. 1982 Mar;10(3):332-9 [7070635.001]
  • [Cites] J Neurosurg. 1984 Mar;60(3):500-5 [6607981.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1139-43 [6491698.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Neurosurgery. 1989 Jan;24(1):12-7 [2927589.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Acta Neurochir (Wien). 1993;122(1-2):60-70 [8333310.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):245-51 [8027808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):315-21 [7673018.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):1-9; discussion 9-10 [8587667.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):915-9; discussion 919-20 [8905745.001]
  • [Cites] Ophthalmology. 1996 Nov;103(11):1761-6; discussion 1766-7 [8942867.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):804-10 [18976068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1324-32 [18922647.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Acta Neurochir (Wien). 2009 Jan;151(1):1-8 [19093071.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1363-70 [11121635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Apr;14(2):103-9 [12069116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):992-1000 [12095568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70 [12128128.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:121-8 [9032852.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Acta Neurol Scand. 1997 Nov;96(5):297-304 [9404999.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:19-32 [9782232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] Stereotact Funct Neurosurg. 1998;71(1):43-50 [10072673.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):75-9 [10219797.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(5):473-80 [10392202.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Nov;61(5):531-43 [15521954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1515-9 [15590183.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14(5):e5 [15669816.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):333-8 [15674748.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • (PMID = 19828022.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2768735
  •  go-up   go-down


38. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol; 2010 May;20(3):623-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas.
  • The gene for the tissue inhibitor of metalloproteinase 3 (TIMP3) on 22q12.3 had been reported to be inactivated by promoter methylation in various types of cancers, with controversial findings in meningiomas.
  • We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas.
  • Moreover, TIMP3 methylation scores were significantly inversely correlated with TIMP3 mRNA expression levels (P = 0.0123), and treatment of the meningioma cell line Ben-Men-1 with demethylating agents induced an increased TIMP3 mRNA expression.
  • TIMP3 is located in the chromosomal band 22q12, the allelic loss of which occurs early in meningioma tumorigenesis and preferentially targets the NF2 tumor suppressor gene.
  • In our tumor panel, all meningiomas with TIMP3 hypermethylation--except for a single case--exhibited allelic losses on 22q12.3.
  • Thus, TIMP3 inactivation by methylation seems fairly exclusive to meningiomas with allelic losses on 22q12 but--in contrast to NF2 mutation--appears to be involved in meningioma progression as it is associated with a more aggressive, high-grade meningioma phenotype.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. DNA Methylation / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / metabolism. Meningioma / genetics. Meningioma / metabolism. RNA Interference / physiology. Tissue Inhibitor of Metalloproteinase-3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922547.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3
  •  go-up   go-down


39. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol; 2009 Dec;35(6):1395-407
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
  • Meningiomas, one of the largest subgroup of intracranial tumours are generally benign, but can progress to malignancy.
  • They are classified into the three World Health Organization grades: benign, atypical and anaplastic meningiomas.
  • We have performed a microarray transcriptomic study on 17 meningiomas of different malignancy using CodeLink Uniset Human Whole Genome Bioarrays to try to distinguish the different grades and histopathological subtypes.
  • Unsupervised hierarchical clustering classified the meningiomas into groups A, B and C, which corresponded to the three grades except for 3 benign meningiomas with higher proliferation indexes and/or recurrence, included in the atypical group.
  • In the benign tumours, we identified genes with signatures specific for fibroblastic meningiomas (FBLN1, Tenascin C and MMP2 encoding extracellular matrix proteins) and for meningothelial meningiomas (MLPH, DEFB1 and FAT3), suggesting different mechanisms involved in the tumorigenesis of these subtypes.
  • This microarray-based expression profiling study revealed candidate genes and pathways that may contribute to a better understanding of the recurrence of a benign meningioma.
  • Our results might make it possible to determine which benign meningiomas might recur despite complete resection, and will provide helpful information for neurosurgeons in the follow-up of the patients.
  • [MeSH-major] Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology


40. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • The meningioma was initially incompletely resected due to invasion of the sagittal sinus.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • The lung lesions were successfully removed surgically and histologically diagnosed as meningothelial meningioma Grade I WHO.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • In the further course, the residual meningioma was completely removed.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


41. Morokoff AP, Zauberman J, Black PM: Surgery for convexity meningiomas. Neurosurgery; 2008 Sep;63(3):427-33; discussion 433-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for convexity meningiomas.
  • OBJECTIVE: Meningiomas that occur over the convexity of the brain are the most common meningiomas, but little has been published about their contemporary management.
  • We aimed to analyze a large series of convexity meningiomas with respect to surgical technique, complication rates, and pathological factors leading to recurrence.
  • METHODS: We retrospectively reviewed 163 cases of convexity meningiomas operated on in our institution by the senior author (PMB) between 1986 and 2005.
  • RESULTS: Convexity tumors represented 22% of all meningiomas operated on.
  • The pathology of the tumors was benign in 144 (88.3%), atypical in 16 (9.8%), and anaplastic/malignant in 3 (1.8%).
  • In six of the cases designated "benign," there were borderline atypical features.
  • The 5-year recurrence rate for benign meningiomas was 1.8%, atypical meningiomas 27.2%, and anaplastic meningiomas 50%.
  • The two cases of benign tumor recurrences involved tumors with borderline atypia and high MIB-1 indices.
  • CONCLUSION: Convexity meningiomas can be safely removed using modern image-guided minimally invasive surgical techniques with a very low operative mortality.
  • Benign convexity meningiomas having a Simpson Grade I complete excision have a very low recurrence rate.
  • The recurrence rates of atypical and malignant tumors are significantly higher, and borderline atypical tumors should be considered to behave more like atypical rather than benign lesions.
  • Longer-term follow-up data are needed to more accurately determine the recurrence rates of benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812953.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, Flickinger JC: Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery; 2008 Jan;62(1):53-8; discussion 58-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery as definitive management of intracranial meningiomas.
  • OBJECTIVE: Stereotactic radiosurgery has become an important primary or adjuvant minimally invasive management strategy for patients with intracranial meningiomas with the goals of long-term tumor growth prevention and maintenance of patient neurological function.
  • We evaluated clinical and imaging outcomes of meningiomas stratified by histological tumor grade.
  • METHODS: The patient cohort consisted of 972 patients with 1045 intracranial meningiomas managed during an 18-year period.
  • RESULTS: The overall control rate for patients with benign meningiomas (World Health Organization Grade I) was 93%.
  • However, for patients with World Health Organization Grade II and III tumors, tumor control was 50 and 17%, respectively.
  • After 10 years, Grade 1 tumors were controlled in 91% (n = 53); in those without histology, 95% (n = 22) were controlled.
  • CONCLUSION: Stereotactic radiosurgery provided high rates of tumor growth control or regression in patients with benign meningiomas with low risk.
  • This study confirms the role of radiosurgery as an effective management choice for patients with small to medium-sized symptomatic, newly diagnosed or recurrent meningiomas of the brain.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300891.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Tropine A, Dellani PD, Glaser M, Bohl J, Plöner T, Vucurevic G, Perneczky A, Stoeter P: Differentiation of fibroblastic meningiomas from other benign subtypes using diffusion tensor imaging. J Magn Reson Imaging; 2007 Apr;25(4):703-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of fibroblastic meningiomas from other benign subtypes using diffusion tensor imaging.
  • PURPOSE: To differentiate fibroblastic meningiomas, usually considered to be of a hard consistency, from other benign subtypes using diffusion tensor imaging (DTI).
  • MATERIALS AND METHODS: From DTI data sets of 30 patients with benign meningiomas, we calculated diffusion tensors and mean diffusivity (MD) and fractional anisotropy (FA) maps as well as barycentric maps representing the geometrical shape of the tensors.
  • Regarding tensor shape, endothelial meningiomas were represented by spherical tensors (80%) corresponding to isotropic diffusion, whereas the fibroblastic meningiomas showed a high percentage (43%) of nonspherical tensors, indicating planar or longitudinal diffusion.
  • In addition, a capsule-like rim of the in-plane diffusion surrounded most meningiomas irrespective of their histological type.
  • CONCLUSION: If these results correlate to the intraoperative findings of meningioma consistency, DTI-based measurement of FA and analysis of the shape of the diffusion tensor is a promising method to differentiate between fibroblastic and other subtypes of benign meningiomas in order to get information about their "hard" or "soft" consistency prior to removal.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17345634.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J: Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas : long-term experience and review of the literature. Strahlenther Onkol; 2006 Nov;182(11):635-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas : long-term experience and review of the literature.
  • PURPOSE: To analyze own long-term results with fractionated stereotactic radiotherapy (FSRT) in patients with benign meningiomas of the cavernous sinus and to review the literature on these rare lesions.
  • PATIENTS AND METHODS: 57 patients were treated with FSRT for benign meningiomas of the cavernous sinus between 01/1990 and 12/2003 at the authors' institution.
  • Histology was WHO grade I in 28/57 lesions, and undetermined in 29/57 lesions.
  • Overall survival for patients with WHO grade I meningiomas was 95.5% after 5 and 10 years.
  • There was one patient with recurrent hyperlacrimation of one eye on the side of the irradiated meningioma.
  • CONCLUSION: These data demonstrate that FSRT is an effective and safe treatment modality for local control of benign cavernous sinus meningiomas with a minimal risk of significant late toxicity.
  • [MeSH-major] Cavernous Sinus. Dose Fractionation. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072520.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 43
  •  go-up   go-down


45. Jung TY, Jung S, Shin SR, Moon KS, Kim IY, Park SJ, Kang SS, Kim SH: Clinical and histopathological analysis of cystic meningiomas. J Clin Neurosci; 2005 Aug;12(6):651-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and histopathological analysis of cystic meningiomas.
  • Between 1993 and 2003, we treated 21 patients with cystic meningioma (of 365 with meningioma, 5.5%).
  • There were five atypical and 16 benign meningiomas on histopathology.
  • In type I and II cystic meningiomas, with intratumoral cysts, all cyst walls enhanced on MRI and had tumor cells in the cyst wall on histopathology.
  • In type III and IV cystic meningiomas, with peritumoral cysts, the cyst wall did not enhance on MRI and only one case (type III) had tumor cells in the cyst wall on histopathology.
  • [MeSH-major] Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098756.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


46. El Husseini M, Ianovici N, Dumitrescu GF, Mihăilă D, Plămădeală P, Haba D, Indrei A: [Posterior fossa meningiomas--topographic and anatomopathologic aspects]. Rev Med Chir Soc Med Nat Iasi; 2010 Jul-Sep;114(3):777-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Posterior fossa meningiomas--topographic and anatomopathologic aspects].
  • Meningiomas are the most frequent met intracranial tumors.
  • MATERIAL AND METHOD: Our study is focused on posterior fosa meningiomas, initially classified according to their origin based on IRM and surgical findings in order to identify correlations between demographic data, topographic tumor origin and anatomopathologic characteristics for each subgroup.
  • 35 posterior fosa meningioma patients that have been subject to neurosurgery in Iaşi "Prof.Dr. N.
  • Benign meningiomas (1st degree) represented the unique subtype in tumors located in cerebellum convexity and foramen magnum.
  • Other locations have different characteristic subtypes (fibrous vs. angiomatous meningioma).
  • [MeSH-major] Cranial Fossa, Posterior / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21243804.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


47. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M: Involvement of PKC-iota in glioma proliferation. Cell Prolif; 2008 Feb;41(1):122-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in vivo, the status and function of PKC-iota in human normal brain tissue, gliomas, benign and malignant meningiomas as well as its in vitro status in proliferating and confluent glioma cells, remains unknown.
  • OBJECTIVES: The objectives of our research were to determine whether expression of PKC-iota is altered either in gliomas or in benign and malignant meningiomas, compared to normal brain.
  • MATERIALS AND METHODS: Western blot analyses for PKC-iota were performed on 12 normal brain biopsies, 15 benign meningiomas, three malignant meningiomas and three gliomas.
  • In comparison, PKC-iota was robustly present in the majority of the benign meningiomas.
  • Similarly, PKC-iota was abundant in all malignant meningiomas and gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211289.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Small Interfering; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


48. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD: Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg; 2008 Jul;110(7):645-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT.
  • OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior.
  • This study evaluated whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake correlates with meningioma proliferative activity, as assessed by flow cytometry analysis.
  • PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied.
  • RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions.
  • There was also a positive correlation between tracer uptake and the level of aneuploidy and tumor grade.
  • CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.
  • [MeSH-major] Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Tomography, Emission-Computed, Single-Photon / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471956.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


49. Chang IB, Cho BM, Moon SM, Park SH, Oh SM, Cho SJ: Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas. J Korean Neurosurg Soc; 2010 Jul;48(1):14-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity at 1p, 7q, 17p, and 22q in meningiomas.
  • OBJECTIVE: Allelic losses or loss of heterozygosity (LOH) at many chromosomal loci have been found in the cells of meningiomas.
  • The objective of this study was to evaluate LOH at several loci of different chromosomes (1p32, 17p13, 7q21, 7q31, and 22q13) in different grades of meningiomas.
  • METHODS: Forty surgical specimens were obtained and classified as benign, atypical, and anaplastic meningiomas.
  • RESULTS: LOH at 1p32 was detected in 24%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively.
  • Whereas LOH at 7q21 was found in only one atypical meningioma.
  • LOH at 7q31 was found in one benign meningioma and one atypical meningioma.
  • LOH at 17p13 was detected in 4%, 40%, and 80% in benign, atypical, and anaplastic meningiomas, respectively.
  • LOH at 22q13 was seen in 48%, 60%, and 60% in benign, atypical, and anaplastic meningiomas, respectively.
  • LOH results at 1p32 and 17p13 showed statistically significant differences between benign and non-benign meningiomas.
  • On the other hand, LOH at 7q21 and 7q31 may not contribute to the development of the meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1984 Sep 6-11;311(5981):29-33 [6590967.001]
  • [Cites] Humangenetik. 1972;14(2):167-9 [4112733.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):178-82 [7829212.001]
  • [Cites] Acta Neuropathol. 1993;85(6):611-6 [8337939.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1115-25 [8622656.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):39-44 [9049861.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Aug;56(8):879-86 [9258258.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Gene. 1998 Jul 17;215(1):159-69 [9666114.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3226-30 [9699646.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):101-6 [9892091.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5995-8 [10606247.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59 [11750879.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10(10):1431-5 [15133848.001]
  • [Cites] Int J Gynaecol Obstet. 2004 Jun;85(3):294-5 [15145275.001]
  • [Cites] Cancer Lett. 2004 Sep 15;213(1):117-24 [15312691.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):794-801 [1436057.001]
  • [Cites] Cell Growth Differ. 1992 Jan;3(1):11-20 [1534687.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1313-8 [1886708.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 [1933891.001]
  • [Cites] Cell. 1986 Jun 20;45(6):895-904 [2423252.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Science. 1971 Aug 27;173(3999):821-2 [4105987.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • (PMID = 20717507.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2916143
  • [Keywords] NOTNLM ; Chromosome / Loss of heterozygosity / Meningiomas
  •  go-up   go-down


50. Martinez-Glez V, Franco-Hernandez C, Alvarez L, De Campos JM, Isla A, Vaquero J, Lassaletta L, Casartelli C, Rey JA: Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. Int J Oncol; 2009 Feb;34(2):493-504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas and schwannomas: molecular subgroup classification found by expression arrays.
  • As the molecular pathogenesis of meningiomas and schwannomas, characterized by NF2 gene alterations, remains unclear and suitable molecular targets need to be identified, we used low density cDNA microarrays to establish expression patterns of 96 cancer-related genes on 23 schwannomas, 42 meningiomas and 3 normal cerebral meninges.
  • Results showed a high frequency of NF2 gene mutations (40%), increased 22q LOH as aggressiveness increased, frequent losses and gains by MLPA in benign meningiomas, and gene expression silencing by hypermethylation.
  • Array analysis showed decreased expression of 7 genes in meningiomas.
  • Unsupervised analyses identified 2 molecular subgroups for both meningiomas and schwannomas showing 38 and 20 differentially expressed genes, respectively, and 19 genes differentially expressed between the two tumor types.
  • These findings provide a molecular subgroup classification for meningiomas and schwannomas with possible implications for clinical practice.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningioma / genetics. Neurilemmoma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148485.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Neoplasm
  •  go-up   go-down


51. Chen J, Xu X, Wang H: Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion. J Huazhong Univ Sci Technolog Med Sci; 2009 Feb;29(1):94-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion.
  • To investigate the expression of integrin-alpha3 mRNA in meningiomas and its correlation with proliferation and invasion, the expression of integrin-alpha(3) subunit was detected by using in situ hybridization in patients with meningiomas (36 cases) and normal dura (2 cases) and arachnoid tissues (2 cases).
  • The results showed that the expression of integrin-alpha(3) mRNA in benign, atypical and malignant meningiomas was 2.52+/-0.362, 1.75+/-0.316 and 1.42+/-0.633, respectively.
  • The expression levels of integrin-alpha(3) mRNA was significantly lower in atypical or malignant meningiomas than those in benign meningiomas (P<0.05, P<0.01, respectively).
  • It suggested that integrin-alpha(3) subunit participated in the modulatory process of growth of meningiomas.
  • The proliferation activity and malignant grade of meningiomas were increased with the decreased expression of integrin-alpha(3) subunit, and the down-regulation of integrin-alpha(3) mRNA was associated with the invasive biological behaviors in meningiomas.
  • [MeSH-major] Integrin alpha3 / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224172.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Integrin alpha3; 0 / RNA, Messenger
  •  go-up   go-down


52. Shah AB, Muzumdar GA, Chitale AR: Meningiomas: report of a hospital-based registry. Indian J Pathol Microbiol; 2005 Oct;48(4):468-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas: report of a hospital-based registry.
  • This is a hospital-based epidemiologic study of meningiomas.
  • Of 1321 central nervous system tumours, meningiomas constituted 21% of the cases, being the second largest category of a single histologic type after astrocytomas.
  • Of the 267 meningiomas studied, 247 were intra-cranial (92.5%).
  • 261 (98%) meningiomas were histologically benign and 5 were malignant meningiomas (1.9%).
  • Of note was the fact, that out of 261 patients with benign meningiomas, 11 succumbed in the immediate post-operative period and in 8 of these cases, the tumour was located at the base of the skull.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366096.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


53. Ginat DT, Mangla R, Yeaney G, Wang HZ: Correlation of diffusion and perfusion MRI with Ki-67 in high-grade meningiomas. AJR Am J Roentgenol; 2010 Dec;195(6):1391-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of diffusion and perfusion MRI with Ki-67 in high-grade meningiomas.
  • OBJECTIVE: Atypical and anaplastic meningiomas have a greater likelihood of recurrence than benign meningiomas.
  • The purpose of this study was to determine the correlation between Ki-67 and regional cerebral blood volume (rCBV) and between Ki-67 and apparent diffusion coefficient (ADC) in atypical and anaplastic meningiomas.
  • MATERIALS AND METHODS: A retrospective review of the advanced imaging and immunohistochemical characteristics of atypical and anaplastic meningiomas was performed.
  • CONCLUSION: Maximum rCBV correlated significantly with Ki-67 in high-grade meningiomas.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21098200.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


54. Bateman BT, Lin E, Pile-Spellman J: Definitive embolization of meningiomas. A review. Interv Neuroradiol; 2005 Jun 30;11(2):179-88

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive embolization of meningiomas. A review.
  • SUMMARY: This review examines the possible role for definitive embolization as a primary therapy for intracranial meningiomas.
  • Surgery or radiosurgery are currently considered the standard of care for most benign meningiomas.
  • There are a few reports of treating meningiomas by embolization without subsequent surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol Suppl. 1976;347:175-86 [207091.001]
  • [Cites] Stroke. 1999 Feb;30(2):317-20 [9933266.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:99-101 [8738507.001]
  • [Cites] Neuroradiology. 2003 Jul;45(7):451-5 [12802546.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Mar;30(3):173-7 [1697044.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Sep-Oct;12(5):977-84 [1950934.001]
  • [Cites] Acta Neurochir (Wien). 1990;107(1-2):47-55 [2096608.001]
  • [Cites] Acta Neurochir (Wien). 1990;102(3-4):98-102 [2336986.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Sep-Oct;7(5):963-72 [3096121.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Neurosurgery. 1983 Sep;13(3):261-8 [6621840.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1984 Mar;60(3):506-11 [6699694.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14(3):571-82 [8517342.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Oct;20(9):1695-702 [10543643.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):666-9 [10782775.001]
  • [Cites] J Neurooncol. 2000 May;48(1):51-5 [11026697.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] J Neurooncol. 2000 Jul;48(3):233-41 [11100821.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1306-11; discussion 1311-2 [11126901.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):89-101 [11301090.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):547-53 [11534671.001]
  • [Cites] Surg Neurol. 2001 Jul;56(1):8-20; discussion 20-1 [11546562.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1231-5; discussion 1235-7 [12015840.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1000-5 [12605979.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1436-40; discussion 1440-2 [12762888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):506-8 [15037482.001]
  • [Cites] Surg Neurol. 1980 Aug;14(2):119-27 [7414494.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):771-3; discussion 773-4 [7808628.001]
  • [Cites] Ann Neurol. 1995 Jan;37(1):67-73 [7818260.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Sep;15(8):1401-7; discussion 1408-11 [7985557.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):59-62 [8042556.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):341-5 [9120445.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neuroradiology. 1997 Dec;39(12):877-80 [9457715.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):446-53; discussion 453-4 [9526976.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):405-13; discussion 413-4 [9733295.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Neurosurg Rev. 1998;21(2-3):106-10 [9795943.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(10):1013-6; discussion 1016-7 [9856244.001]
  • [Cites] Br J Neurosurg. 1992;6(2):131-7 [1590966.001]
  • (PMID = 20584499.001).
  • [ISSN] 1591-0199
  • [Journal-full-title] Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
  • [ISO-abbreviation] Interv Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3399720
  •  go-up   go-down


55. Das A, Tan WL, Smith DR: p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg; 2005 Jan;28(1):7-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 point mutation is rare in meningiomas from Singaporean patients.
  • In Asian populations, meningiomas account for up to 35% of all central nervous system tumours, a significantly higher incidence than in Caucasian populations.
  • While several studies have examined p53 both at the level of the gene and the protein in both benign and malignant meningiomas, its role remains controversial, particularly with regard to the discrepancy between p53 over-expression and gene mutation.
  • We examined 19 benign meningiomas, all of which were known to over-express p53, and eight malignant meningiomas, of which three were known to over-express p53, for mutations in the p53 gene using polymerase chain reaction amplification and direct sequencing of exons 4 to 9, inclusive.
  • Only one single mutation was detected in a benign meningioma, confirming that p53 over-expression in meningiomas is commonly found in the absence of gene mutations, and that despite the significantly higher incidence of meningiomas in some Asian populations, this is not associated with a significantly higher rate of p53 mutations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691789.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


56. Fotopoulos AD, Alexiou GA, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Tsiouris S: (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol; 2008 Sep;89(2):225-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.
  • Meningiomas account for about 30% of all intracranial tumors.
  • We evaluated prospectively whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake in meningiomas correlates with cellular proliferative activity and with tumor grade.
  • We prospectively studied 18 meningioma cases.
  • 14 of 18 patients had benign meningiomas, while the remaining four had anaplastic meningiomas.
  • A significant correlation was found between both (99m)Tc-TF uptake and tumor grade (r = 0.722, P = 0.001) and between (99m)Tc-TF uptake and Ki-67 expression (r = 0.930, P < 0.001).
  • This pilot study implies that (99m)Tc-TF brain SPECT could prove useful in differentiating benign from anaplastic meningiomas and is a potential indicator of their proliferative activity.
  • [MeSH-major] Brain / radionuclide imaging. Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


57. Ng WH, Cheong DL, Khu KJ, Venkatesh G, Ng YK, Lim CC: Diffusion tensor tractography: corticospinal tract fiber reduction is associated with temporary hemiparesis in benign extracerebral lesions. Neurosurgery; 2008 Sep;63(3):452-8; discussion 458-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor tractography: corticospinal tract fiber reduction is associated with temporary hemiparesis in benign extracerebral lesions.
  • OBJECTIVE: Benign extracerebral lesions such as meningiomas may cause hemiparesis by compression and deviation without infiltrating the white matter.
  • We used magnetic resonance diffusion tensor imaging and diffusion tensor tractography to investigate the effects of benign extracerebral lesions on the corticospinal tract (CST).
  • METHODS: Thirteen patients with extracerebral lesions (11 benign meningiomas and 2 benign cysts) underwent magnetic resonance diffusion tensor imaging and diffusion tensor tractography of the CST using fiber assignment by continuous tractography.
  • CONCLUSION: In patients with benign extracerebral lesions, reduction in fiber number and fiber per voxel, but not fiber deviation, correlated with temporary hemiparesis.
  • Clinical recovery was possible even if the CST fibers detected by diffusion tensor tractography were reduced by benign extracerebral lesions.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / adverse effects. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / adverse effects. Paresis / etiology. Pyramidal Tracts / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812956.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, Shen TZ, Chen XR: Lipid signal in evaluation of intracranial meningiomas. Chin Med J (Engl); 2008 Dec 5;121(23):2415-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid signal in evaluation of intracranial meningiomas.
  • BACKGROUND: Using magnetic resonance imaging, diagnosis of malignant meningioma from benign meningioma with atypical features is uncertain.
  • We evaluated the value of lipid signal in differentiating intracranial meningiomas.
  • RESULTS: Twenty-nine meningiomas were histologically benign (eleven meningothelial, thirteen fibrous, four transitional and one microcystic), three were atypical, and two were anaplastic.
  • Lipid signal was detected in ten cases: two anaplastic, three atypical, two fibrous and three meningothelial meningiomas.
  • With creatinine peak in the normal white matter chosen as internal standard, lipid/creatinine ratios of anaplastic, atypical and benign meningiomas were 0.844 +/- 0.027 (range from 0.725 to 0.994), 0.465 +/- 0.023 (range from 0.239 to 0.724), and 0.373 +/- 0.016 (range from 0.172 to 0.571) respectively.
  • Patchy necrosis was observed in anaplastic meningioma, while focal necrosis was noted in atypical meningioma with HE stain.
  • However, no necrosis was found in benign group.
  • KP-1 stain demonstrated histocytes containing lipids in the necrotic region of anaplastic and atypical meningioma.
  • CONCLUSION: The lipid signal at 1.3 ppm is a useful marker in evaluating the malignancy of intracranial meningiomas, especially in the differential diagnosis of anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102960.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Al-Khalaf HH, Lach B, Allam A, AlKhani A, Alrokayan SA, Aboussekhra A: The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol; 2007 May;83(1):9-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined.
  • In the present study we have used the immuno-blotting technique to study the expression level of the tumor suppressor proteins p53, p21 and PTEN in primary meningioma cells.
  • These results suggest that the tumor suppressors p53/p21 signaling pathway and PTEN play important roles in the development of benign meningiomas.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / genetics. DNA Damage. Genes, p53. Meningeal Neoplasms / genetics. Meningioma / genetics. Signal Transduction

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245624.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Membrane Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / TPTE protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


60. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunities for clinical research in meningioma.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


61. Vranic A: Antigen expression on recurrent meningioma cells. Radiol Oncol; 2010 Jun;44(2):107-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen expression on recurrent meningioma cells.
  • INTRODUCTION: Meningiomas are intracranial brain tumours that frequently recur.
  • Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported.
  • The most important prognostic factors for meningioma recurrence are meningioma grade, meningioma invasiveness and radicality of neurosurgical resection.
  • The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas.
  • METHODS: 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry.
  • RESULTS: MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001).
  • No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed.
  • Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p<0.001) were both higher in the recurrent than in the non-recurrent meningioma group.
  • CONCLUSIONS: [corrected] MIB-1 antigen expression is higher in recurrent compared to non-recurrent meningiomas.
  • There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas.
  • Cathepsins B and L are expressed more in recurrent meningiomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Jul;91(1):93-9 [10389886.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2001 Mar;48(3):598-605 [11270551.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):839-44 [11702875.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):71-6 [12952288.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1547-53 [15735044.001]
  • [Cites] Int J Biol Markers. 2005 Jan-Mar;20(1):50-9 [15832773.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):170-4 [16033133.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):415-21 [16564915.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Radiol Oncol. 2010 Mar;44(1):1-12 [22933884.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):178-87 [15043715.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):123-8 [12520707.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):285-90 [7542317.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):27-34 [8521613.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):559-67 [10100707.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • (PMID = 22933900.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423683
  • [Keywords] NOTNLM ; cathepsin B / cathepsin L / meningioma / proliferation index, MIB-1 antigen / recurrence / tumour markers
  •  go-up   go-down


62. Kondraganti S, Gondi CS, McCutcheon I, Dinh DH, Gujrati M, Rao JS, Olivero WC: RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth. Int J Oncol; 2006 Jun;28(6):1353-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.
  • Similar to gliomas, malignant meningiomas also exhibit elevated protease levels in comparison to normal brain and benign meningiomas.
  • As determined by Western blotting and fibrin zymography, pU2 effectively inhibited uPAR protein levels and uPA enzymatic activity in meningioma cells (IOMM-Lee).
  • In vitro studies (Matrigel invasion and spheroid migration) revealed reduced meningioma cell invasion and migration.
  • In addition, in vivo studies of mice injected with pU2-transfected meningioma cells revealed inhibition of intracranial tumor formation.
  • These findings suggest that siRNA can be used as a potent and specific therapeutic tool for the treatment of malignant meningiomas in humans.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19382-8 [10777511.001]
  • [Cites] Nat Biotechnol. 2000 Aug;18(8):896-8 [10932163.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Am J Manag Care. 2000 Sep;6(14 Suppl):S746-60 [11184072.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1191-200 [11050387.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5839-47 [11059781.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 1;56(1-2):104-32 [11213252.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):2032-43 [11360187.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2519-26 [11489835.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12479-85 [11805108.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Haemostasis. 2001;31 Suppl 1:59 [11990482.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5716-24 [12173041.001]
  • [Cites] FEBS Lett. 2002 Sep 25;528(1-3):212-6 [12297307.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7824-30 [12420219.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):635-7 [12754523.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Chembiochem. 2005 Feb;6(2):441-3 [15651038.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] BMC Biotechnol. 2003 Nov 6;3:21 [14604435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14883-8 [15466709.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):783-92 [2166055.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):274-81 [1988089.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4143-7 [8395977.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:13-31 [1339241.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):3983-91 [8076594.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32380-8 [7528215.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] Invasion Metastasis. 1995;15(1-2):34-45 [7672930.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2428-33 [8625323.001]
  • [Cites] Clin Exp Metastasis. 1996 May;14(3):297-307 [8674284.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Science. 1996 Sep 13;273(5281):1551-5 [8703217.001]
  • [Cites] J Cell Biol. 1997 May 5;137(3):767-77 [9151680.001]
  • [Cites] J Cell Sci. 1997 May;110 ( Pt 9):1091-8 [9175705.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1351-9 [9178895.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):285-96 [9198168.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):58-67 [9202057.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):440-6 [9219733.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4522-31 [9373263.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1861-72 [9412478.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Clin Exp Metastasis. 1998 May;16(4):353-7 [9626814.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):377-85; discussion 385-6 [9689330.001]
  • [Cites] Nature. 1998 Oct 29;395(6705):854 [9804418.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4499-504 [9891516.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3369-73 [10416596.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8486-96 [15378018.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):123-34 [10591631.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Nov 1;9(21):3147-52 [10560742.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5307-14 [10537314.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Trends Biochem Sci. 2000 Feb;25(2):53-9 [10664583.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):298-304 [10605717.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):371-8 [15372045.001]
  • (PMID = 16685436.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / CA75557; United States / NCI NIH HHS / CA / CA116708; United States / NCI NIH HHS / CA / CA95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA92393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS9142; NLM/ PMC1459538
  •  go-up   go-down


63. Lee JH, Sade B, Choi E, Golubic M, Prayson R: Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg; 2006 Jul;105(1):60-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma.
  • OBJECT: This study was undertaken to test a hypothesis that meningiomas of the midline skull base and spine are predominantly of the meningothelial histological subtype.
  • METHODS: The cases of 794 consecutive patients who underwent resection for meningioma at the Cleveland Clinic between January 1991 and March 2004 were reviewed retrospectively.
  • The authors analyzed the relationship between the tumors' histological subtypes and sites of origin in the 731 patients from this group who harbored tumors that were determined to be benign histologically (World Health Organization Grade I).
  • Meningothelial meningiomas (MMs) accounted for 63.5% (464/731) of the Grade I tumors.
  • CONCLUSIONS: Meningiomas of the midline neuraxis are predominantly meningotheliomas.
  • Analysis of the increasingly available data on genetic and topographic characteristics of MMs suggests that they may represent a unique entity, contrary to the prevailing belief that all benign meningiomas are identical tumors.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Base Neoplasms / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871881.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Gläsker S, Sohn TS, Zeng W, Ikejiri B, Proescholdt MA, Mayer C, Weil RJ, Oldfield EH, Zhuang Z: Comparative proteomic profiles of meningioma subtypes. Cancer Res; 2006 Oct 15;66(20):10199-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic profiles of meningioma subtypes.
  • Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics.
  • Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors.
  • Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone.
  • We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns.
  • Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced.
  • Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype.
  • Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas.
  • We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades.
  • The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningioma / classification

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047085.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


65. Erkutlu I, Buyukhatipoglu H, Alptekin M, Berkyurek E, Tutar E, Gok A: Spinal drop metastases from a papillary meningioma: a case report and review of the literature: utility of CSF sampling. Med Oncol; 2009;26(2):242-6
Genetic Alliance. consumer health - Meningioma, spinal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal drop metastases from a papillary meningioma: a case report and review of the literature: utility of CSF sampling.
  • In this paper, we report a rare case of a 29-year-old boy who presented with papillary meningioma originating from the posterior fossa meninges.
  • In this report, we briefly discuss an exceedingly rare variant of meningioma, the papillary variant, and suggest a new approach, a CSF sampling, in the management of both malignant and benign meningiomas.
  • Furthermore, we discussed that meningiomas are tumors that are not as benign as initially thought.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / secondary. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937081.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


66. Lee JY, Kondziolka D, Flickinger JC, Lunsford LD: Radiosurgery for intracranial meningiomas. Prog Neurol Surg; 2007;20:142-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for intracranial meningiomas.
  • INTRODUCTION: Meningiomas are common intracranial benign tumors that can be surgically excised.
  • MATERIALS AND METHODS: Between September 1987 and December 2004, 964 patients underwent Gamma Knife radiosurgery at the University of Pittsburgh for the diagnosis of meningioma.
  • RESULTS: Overall, Gamma Knife radiosurgery provides 5- and 10-year actuarial tumor control rates of 93% for benign meningiomas.
  • The 5-year actuarial control rate for patients with atypical and malignant meningiomas was 83 +/- 7 and 72 +/- 10%, respectively.
  • CONCLUSION: Gamma Knife radiosurgery is an attractive option for patients with intracranial meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317982.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Yoo-Jin K, Kim Y, Bochem N, Ketter R, Henn W, Feiden W: [Meningiomas: multiparametric approach for risk stratification and grading]. Pathologe; 2008 Nov;29(6):428-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningiomas: multiparametric approach for risk stratification and grading].
  • The prognosis of the generally benign meningiomas is mainly an issue of the likelihood of recurrence, which increases with WHO grade (7-20% in WHO grade I, 29-40% in WHO grade II, and 50-78% in WHO grade III meningiomas).
  • As the cutoffs of the mitotic index (MI) are defined for each grade by the WHO classification of brain tumors and because the MI can be applied as the sole grading criterion, the reliable and reproducible assessment of the MI is crucial for an appropriate risk stratification.
  • The Ki-67 labeling index provides additional prognostic information, especially in prognostically ambiguous meningiomas.
  • [MeSH-major] Chromosomes, Human, Pair 1. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810442.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Friedman WA, Murad GJ, Bradshaw P, Amdur RJ, Mendenhall WM, Foote KD, Bova FJ: Linear accelerator surgery for meningiomas. J Neurosurg; 2005 Aug;103(2):206-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear accelerator surgery for meningiomas.
  • OBJECT: In this paper the authors review the results of a single-center experience in the use of linear accelerator (LINAC) surgery for radiosurgical treatment of meningiomas.
  • METHODS: A retrospective analysis of all patients treated with LINAC surgery for meningiomas between May 1989 and December 2001 was performed.
  • The actuarial local control rate for benign tumors was 100% at both 1 and 2 years, and 96% at 5 years.
  • In all patients with a permanent complication the histological characteristics of the meningioma were malignant.
  • CONCLUSIONS: Linear accelerator surgery produced high local control rates and very low rates of permanent morbidity in patients harboring benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 Aug;103(2):203-5; discussion 205 [16175846.001]
  • (PMID = 16175847.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • Lung metastatic meningiomas may be a diagnostic challenge because of their unusual site of presentation and the possible confusion with primitive lung meningiomas or primary mesenchymal lung lesions.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer; 2007;6:64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular signatures define two main classes of meningiomas.
  • BACKGROUND: Meningiomas are common brain tumors that are classified into three World Health Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors.
  • The purpose of this study was identify molecular signatures unique to the different grades of meningiomas and to unravel underlying molecular mechanisms driving meningioma tumorigenesis.
  • RESULTS: We have used a combination of gene expression microarrays and array comparative genomic hybridization (aCGH) to show that meningiomas of all three grades fall into two main molecular groups designated 'low-proliferative' and 'high-proliferative' meningiomas.
  • While all benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the high-proliferative group, atypical meningiomas distribute into either one of these groups.
  • High-proliferative atypical meningiomas had an elevated median MIB-1 labeling index and a greater frequency of copy number aberrations (CNAs) compared to low-proliferative atypical meningiomas.
  • Additionally, losses on chromosome 6q, 9p, 13 and 14 were found exclusively in the high-proliferative meningiomas.
  • We have identified genes that distinguish benign low-proliferative meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-proliferation markers and loss of components of the transforming growth factor-beta signaling pathway were the major molecular mechanisms that distinguish these two groups.
  • CONCLUSION: Collectively, our data suggests that atypical meningiomas are not a molecularly distinct group but are similar to either benign or malignant meningiomas.
  • It is anticipated that identified molecular and CNA markers will potentially be more accurate prognostic markers of meningiomas.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics. Nucleic Acid Hybridization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Genome Biol. 2003;4(1):R7 [12540299.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 17937814.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2173907
  •  go-up   go-down


71. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • Clinical suspicion in both patients was an atypical or anaplastic meningioma due to the edema.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Caffo M, Caruso G, Germanò A, Galatioto S, Meli F, Tomasello F: CD68 and CR3/43 immunohistochemical expression in secretory meningiomas. Neurosurgery; 2005 Sep;57(3):551-7; discussion 551-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD68 and CR3/43 immunohistochemical expression in secretory meningiomas.
  • OBJECTIVE: Secretory meningiomas (SMs) are unusual benign meningiomas.
  • CONCLUSION: Macrophage infiltration and major histocompatibility complex Class II immunoreactivity in this subtype of meningioma suggest the occurrence of an immune response in the presence of SM.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Immunohistochemistry / methods. Macrophage-1 Antigen / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145535.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Macrophage-1 Antigen
  •  go-up   go-down


73. Nakasu S, Fukami T, Nakajima M, Watanabe K, Ichikawa M, Matsuda M: Growth pattern changes of meningiomas: long-term analysis. Neurosurgery; 2005 May;56(5):946-55; discussion 946-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth pattern changes of meningiomas: long-term analysis.
  • OBJECTIVE: Although tumors are generally expected to grow exponentially, it is not known whether meningiomas retain a constant growth rate or not because of the lack of long-term follow-up.
  • We analyzed the long-term growth pattern of meningiomas.
  • METHODS: Twenty patients with a total of 31 meningiomas were radiologically followed for 4.1 to 18.3 years (median, 10.1 yr).
  • RESULTS: The growth curves of four atypical meningiomas fitted better to an exponential curve (R > 0.95).
  • Although the other benign tumors grew exponentially or linearly, their tumor volume doubling times in the initial phase were shorter than those in the later phase in most cases.
  • Meningiomas without calcification tended to grow exponentially, whereas those with calcification were likely to reveal a linear growth pattern (P = 0.002, chi2 test).
  • CONCLUSION: Three growth patterns of meningiomas were demonstrated.
  • Atypical meningiomas grew exponentially.
  • Conversely, benign meningiomas revealed exponential, linear, or no growth.
  • [MeSH-major] Cell Division / physiology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854242.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Stremenová J, Mares V, Lisá V, Hilser M, Krepela E, Vanicková Z, Syrucek M, Soula O, Sedo A: Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas. Int J Oncol; 2010 Feb;36(2):351-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
  • Meningiomas are tumors derived from arachnoid cap cells that represent approximately 30% of all intracranial tumors.
  • In this study, we investigated 22 human meningiomas for the expression of dipeptidyl peptidase (DPP)-IV activity and/or structure homologs (DASH), including canonical DPP-IV/CD26, fibroblast activation protein-alpha (FAPalpha), DPP8 and DPP9.
  • DPP-IV-like enzymatic activity, including all enzymatically-active DASH molecules, was found in all 18 benign meningiomas WHO grade I and IV atypical meningiomas WHO grade II by continuous rate fluorimetric assay in tissue homogenates and catalytic enzyme histochemistry in situ.
  • In atypical meningiomas, this activity was significantly higher and was associated with higher cell proliferation as detected by Ki67 antigen immunohistochemistry.
  • Expression of CXCR4, the receptor of pro-proliferative chemokine stromal cell-derived factor-1alpha (SDF-1alpha), DPP-IV substrate, was found in all tumors, suggesting higher values in atypical grade II samples.
  • This is the first report on the expression status of dipeptidyl peptidase-IV and related molecules in meningiomas.
  • In addition, the study suggests an increase of DPP-IV-like enzymatic activity in these tumors of WHO grade II.
  • [MeSH-major] Dipeptidases / metabolism. Dipeptidyl Peptidase 4 / metabolism. Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / metabolism. Meningeal Neoplasms / enzymology. Meningioma / enzymology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043068.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / RNA, Messenger; EC 3.4.13.- / Dipeptidases; EC 3.4.14.- / DPP9 protein, human; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.5 / DPP8 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


75. Park KJ, Kang SH, Chae YS, Yu MO, Cho TH, Suh JK, Lee HK, Chung YG: Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg; 2010 Jan;112(1):73-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas.
  • OBJECT: Peritumoral brain edema (PTBE) is associated with perioperative neurological deficits in patients with meningiomas.
  • However, the pathogenesis of meningioma-associated edema remains unclear.
  • In the present study, the authors investigated the expression of interleukin-6 (IL-6) and its relationship with PTBE in resected meningiomas.
  • METHODS: Thirty-six benign meningiomas obtained in 36 patients were studied retrospectively.
  • On immunohistochemical analysis, IL-6 protein was found localized in the cytoplasm of the tumor cells, and was detected in 12 (75%) of 16 cases of edematous meningiomas, but in only 6 (30%) of 20 nonedematous cases.
  • CONCLUSIONS: The authors' results in this study indicate that IL-6 expression may contribute to the development of brain edema associated with meningiomas.
  • [MeSH-major] Brain Edema / etiology. Brain Edema / metabolism. Brain Neoplasms / surgery. Interleukin-6 / metabolism. Meningioma / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):208. Yoo, Mi-Ok [corrected to Yu, Mi-Ok]
  • (PMID = 19445568.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger
  •  go-up   go-down


76. Sayagués JM, Tabernero MD, Maíllo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A: Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. J Neuropathol Exp Neurol; 2006 May;65(5):445-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression.
  • It has long been recognized that spinal meningiomas show particular clinical and histological features.
  • Here, we compare the clinico-biological characteristics as well as the genetic abnormalities and patterns of gene expression of spinal and intracranial meningiomas.
  • Fourteen spinal and 141 intracranial meningioma patients were analyzed at diagnosis.
  • Additionally, microarray analyses were performed on a subgroup of 18 histologically benign meningiomas (7 spinal and 11 intracranial).
  • Upon comparison with intracranial tumors, spinal meningiomas showed a marked predominance of psammomatous and transitional tumors (p = 0.001), together with a higher proportion of cases displaying a single tumor cell clone by iFISH (p = 0.004).
  • Analysis of gene expression profiles showed differential expression between spinal and intracranial meningiomas for a total of 1555 genes, 35 of which allowed a clear distinction between both tumor types.
  • In summary, we show the occurrence of unique patterns of genetic abnormalities and gene expression profiles in spinal as compared to intracranial meningiomas that provide new insights into the molecular pathways involved in the tumorigenesis and progression of spinal meningiomas, and could help explain their particular clinical and histological features.
  • [MeSH-major] Gene Expression / physiology. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772868.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


77. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res; 2005 Jun 1;11(11):4074-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
  • PURPOSE: Activation of intracellular signaling cascades has been implicated in the growth control of benign meningiomas, but their role for meningioma progression and outcome is unknown.
  • Here we determined the expression and function of proteins involved in mitogen-activated protein kinase (MAPK) and phosphinositol-3 kinase (PI3K)/Akt signaling in benign, atypical, and malignant meningiomas and studied their association with clinicopathologic data including meningioma recurrence.
  • EXPERIMENTAL DESIGN: Expression of various MAPK and PI3K signaling proteins was determined in 70 primary meningiomas and, if present, in recurrent tumors by immunohistochemistry and Western blotting.
  • The effect of MAPK and PI3K pathway inhibition on cell proliferation and apoptosis was determined using a primary malignant meningioma cell culture.
  • RESULTS: Atypical and malignant meningiomas showed higher levels of phospho-Akt compared with benign tumors, and their proliferation could be inhibited by PI3K blocking using wortmannin.
  • PI3K inhibition did not induce apoptosis in malignant meningioma cells.
  • In contrast, expression of phospho-Raf and phospho-MAPK was decreased in aggressive meningiomas compared with benign tumors, but MAPK inhibition by PD98059 resulted in tumor cell apoptosis and decreased proliferation.
  • Reduced MAPK activation was associated with meningioma recurrence, and PI3K activation was associated with poor preclinical condition and brain invasion of malignant meningiomas.
  • CONCLUSIONS: Both MAPK and PI3K/Akt pathways are activated at different levels in benign and malignant meningiomas.
  • Activation of PI3K/Akt signaling contributes to the aggressive behavior of malignant meningiomas, whereas MAPK activation is involved in both proliferation and apoptosis of malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Mitogen-Activated Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930342.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Androstadienes; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Platelet-Derived Growth Factor; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / raf Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.3 / Phospholipase C gamma; EC 3.6.5.2 / ras Proteins; XVA4O219QW / wortmannin
  •  go-up   go-down


78. Püttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, Paulus W: Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest; 2005 Sep;85(9):1163-71
Cellosaurus - a cell line knowledge resource. culture/stock collections - Ben-Men-1 (CVCL_1959) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a benign meningioma cell line by hTERT-mediated immortalization.
  • Meningioma represents the most common intracranial tumor, but well-characterized cell lines derived from benign meningiomas are not available.
  • A major reason for the lack of benign tumor cell lines is senescence of nonmalignant cells in vitro, while malignant cells are often immortal.
  • We have developed a meningioma cell line by retrovirally transducing primary cells derived from a human WHO grade I meningothelial meningioma with the human telomerase reverse transcriptase (hTERT) gene, which enables bypassing cellular senescence.
  • One clone, designated Ben-Men-1, was characterized in more detail, and exhibited typical cytological, immunocytochemical, ultrastructural and genetical features of meningioma, including whorl formation, expression of epithelial membrane antigen, desmosomes and interdigitating cell processes, as well as -22q.
  • Following subdural transplantation into nude mice, tumor tissue with typical histological features of meningothelial meningioma was found.
  • We conclude that Ben-Men-1 represents an immortalized yet differentiated cell line useful for biological and therapeutical studies on meningioma.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. DNA-Binding Proteins / genetics. Meningioma / pathology. Telomerase / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965488.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


79. Durand A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Fèvre-Montange M: Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol; 2008 Sep-Oct;27(5):334-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
  • Meningiomas, which originate from arachnoid cells, represent one of the largest subgroups of intracranial tumors.
  • They are generally benign, but can progress to malignancy.
  • The aim of our study was to determine the expression of 4 genes, c-Myc, neurofibromatosis Type 2 (NF2), somatostatin receptor isoform 2 (sst2) and erb-B2, that have been associated with tumorogenesis or, possibly, with aggressive behavior or recurrence of meningiomas.
  • We measured levels of mRNAs coding for these genes by qRT-PCR in 51 cases and levels ofc-Myc protooncogene and sst2 protein by immunohistochemistry in 26 cases of meningiomas of various grades and histotypes.
  • C-Myc mRNA and protein levels were not grade-related, but validated subdivision of the 36 benign meningiomas into two groups, Groups IA and IB, based on histological and clinical features (Ki-67-proliferative index, absence or presence of mitoses, rate of recurrence and incidence of perilesional edema).
  • In addition to histopathological grading, c-Myc expression may be useful in predicting tumor recurrence in patients with low-grade meningiomas.
  • NF2 mRNA levels and sst2 mRNA and receptor levels were not grade-related, but were histotype-related, with significantly higher levels in the meningothelial subtype than in the fibroblastic subtype.
  • Erb-B2 mRNA levels were not grade- or histotype-related.
  • Furthermore, the high expression of sst2 in meningothelial meningioma suggests the possibility of a different tumorigenesis process in this meningioma subtype and may open perspectives for the diagnosis and therapy of this subtype using somatostatin as an antiproliferative agent.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neurofibromin 2 / biosynthesis. Proto-Oncogene Proteins c-myc / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptors, Somatostatin / biosynthesis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808065.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Neurofibromin 2; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


80. Ruiz J, Martínez A, Hernández S, Zimman H, Ferrer M, Fernández C, Sáez M, López-Asenjo JA, Sanz-Ortega J: Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Histol Histopathol; 2010 03;25(3):341-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
  • The WHO grading scheme distinguishes benign (grade I), atypical (grade II) and anaplastic (grade III) meningiomas.
  • Both atypical and anaplastic meningiomas exhibited an overall increased rate of recurrence, but between 15-20% benign meningiomas will also exhibit an unfavourable clinical course with recurrence before 10 years despite aggressive surgery.
  • We investigated 247 cases of meningiomas grade I and II.
  • The study revealed a statistically significant co-variation (p<0.05) between meningiomas grade II associated with several clinicopathological features (Simpson grade of clinical resection, necrosis, nuclear atypia, macronucleoli, transition to small cell, sheet-like growth, high cellularity), increased expression of several biomarkers of tumour proliferation (Cyclin A, Cyclin E, MIB-1 or MDM2), proteases (Cathepsin D) or cell-adhesion (CD44) and lower expression of progesterone receptors than meningiomas grade I.
  • The expression of COX-2, gamma-catenin, Topoisomerase IIa, VEGF and MIB-1 was significantly higher in the cohort of recurrent meningiomas.
  • Meningiomas with chromosome 1p36 loss showed a higher recurrence rate (33.3%) than meningiomas with normal chromosome 1p36 (18%).
  • Increased COX-2 expression in recurrent meningioma may also suggest a putative role of COX-2 inhibitors as a chemopreventive treatment for recurrence.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054806.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


81. Okuducu AF, Zils U, Michaelis SA, Mawrin C, von Deimling A: Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer; 2006 Sep 15;107(6):1365-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9.
  • It has been demonstrated that the MMPs are expressed strongly in high-grade meningiomas.
  • To determine the biologic significance of Ets-1 in the progression of benign meningiomas, the authors investigated the expressions of Ets-1 and its target genes MMP-2 and MMP-9 in primary and recurrent, Grade 1 meningiomas.
  • METHODS: The expression levels of Ets-1, MMP-2, and MMP-9 were examined by immunohistochemistry in 70 Grade 1 meningiomas, including 36 primary tumors without recurrence after 5 years of follow-up and 17 pairs of primary tumors and subsequent recurrences.
  • RESULTS: The results demonstrated higher expression of Ets-1, MMP-2, and MMP-9 proteins in meningiomas with subsequent recurrences compared with meningiomas from patients who had no recurrences (P < .001).
  • CONCLUSIONS: Ets-1 may be involved in meningioma recurrence by up-regulating MMP-2 and MMP-9.
  • Increased expression of these genes in World Health Organization grade 1 meningiomas may serve as an indicator for a high risk of recurrence.
  • [MeSH-major] Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 9 / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Proto-Oncogene Protein c-ets-1 / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16894529.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


82. Nakasu S, Fukami T, Jito J, Matsuda M: Microscopic anatomy of the brain-meningioma interface. Brain Tumor Pathol; 2005;22(2):53-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic anatomy of the brain-meningioma interface.
  • We analyzed the relation between meningioma and the brain in 50 surgical cases.
  • So-called capsule formation was seen in 20 meningiomas, of which 13 were categorized as thin and 7 as thick.
  • In 21 meningiomas the arachnoid membrane was intact, and 10 meningiomas had no underlying arachnoid membrane.
  • The degree of arachnoid disruption correlated with the tumor grade, perifocal edema, pial blood supply on angiography, and tumor size.
  • The existence of brain invasion correlated with the tumor grade and partially with tumor size.
  • Meningiomas were usually demarcated by a basement membrane that was collagen type 4 (Col4)-positive.
  • However, atypical and anaplastic meningiomas usually lacked Col4 staining at the interface.
  • In two benign meningiomas that looked like an invasive growth, Col4 staining was seen above the brain.
  • [MeSH-major] Brain / ultrastructure. Meningeal Neoplasms / ultrastructure. Meningioma / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095106.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


83. Dijkstra M, van Nieuwenhuizen D, Stalpers LJ, Wumkes M, Waagemans M, Vandertop WP, Heimans JJ, Leenstra S, Dirven CM, Reijneveld JC, Klein M: Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry; 2009 Aug;80(8):910-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late neurocognitive sequelae in patients with WHO grade I meningioma.
  • BACKGROUND: Information on neurocognitive outcome following treatment of benign meningiomas is virtually lacking.
  • The aim of the present study was therefore to document the extent and nature of neurocognitive deficits in patients with World Health Organization (WHO) grade I meningioma after treatment.
  • METHODS: 89 patients with WHO grade I meningioma who underwent surgery with or without adjuvant radiotherapy were individually matched to 89 healthy controls for age, sex and educational level.
  • RESULTS: Compared with healthy controls, patients with meningioma showed significant impairments in executive functioning (p<0.001), verbal memory (p<0.001), information processing capacity (p = 0.001), psychomotor speed (p = 0.001) and working memory (p = 0.006).
  • Patients with skull base meningiomas performed significantly lower on three out of six neurocognitive domains compared with convexity meningiomas.
  • Left-sided as opposed to right-sided meningiomas were related to verbal memory deficits.
  • CONCLUSIONS: Meningioma patients are characterised by long term deficits in neurocognitive functioning that can partly be attributed to the use of antiepileptic drugs and tumour location but not to the use of radiotherapy.
  • [MeSH-major] Cognition Disorders / etiology. Meningioma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653549.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


84. Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T: Early malignant transformation of a petroclival meningothelial meningioma. Neurosurg Rev; 2009 Oct;32(4):495-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early malignant transformation of a petroclival meningothelial meningioma.
  • Although some authors have reported the malignant transformation of meningiomas, there has been no previous report describing that a meningothelial meningioma transformed into an atypical meningioma within 1 year.
  • This report documents a 57-year-old woman who presented with right hearing disturbance.
  • Magnetic resonance imaging revealed a right petroclival meningioma.
  • The tumor was subtotally removed and was diagnosed to be a meningothelial meningioma.
  • The diagnosis of this recurrent tumor was an atypical meningioma.
  • These results suggest that the present case had a potentially malignant tumor in the early stage, although it had the histological features of benign meningiomas.
  • An evaluation of the MIB-1 index, as well as the expression of p53 and chromosomal aberrations, may be useful for predicting the malignant transformation of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19533187.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


85. Lusis EA, Chicoine MR, Perry A: High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol; 2005 Jul;73(3):219-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High throughput screening of meningioma biomarkers using a tissue microarray.
  • Meningiomas are histologically and clinically diverse CNS neoplasms with few available immunohistochemical markers of differentiation and progression.
  • Therefore, we investigated a panel of potentially useful meningioma-associated biomarkers using high throughput tissue microarray immunohistochemistry (TMA-IHC) with a TMA that includes 9 hemangiopericytomas (HPCs) and 41 meningiomas spanning all grades, as well as two subsets of atypical meningiomas, stratified according to clinical behavior.
  • EMA, E-cadherin, and PDGFR-beta staining patterns distinguished the anaplastic meningiomas from the HPCs (P < 0.001, P = 0.02, P = 0.015, respectively).
  • As in prior studies, PR and cathepsin D expression were inversely proportional to tumor grade.
  • However, PR and EGFR were also differentially expressed between symptomatic, surgically resected benign meningiomas and incidental meningiomas found at autopsy.
  • We conclude that (1) TMA-IHC is an accurate and efficient way to rapidly assess biomarkers in meningeal tumors, (2) EMA, E-cadherin, and PDGFR-beta are useful in distinguishing anaplastic meningiomas from HPCs, and (3) the expression patterns for incidental meningiomas differ slightly from their surgically resected symptomatic counterparts.
  • [MeSH-major] Biomarkers, Tumor / analysis. Histocytological Preparation Techniques. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis


86. Perry A, Lusis EA, Gutmann DH: Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. Brain Pathol; 2005 Apr;15(2):109-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to elucidate the nature of this lesion, 11 cases defined by the presence of nests of 10 or more cell layers thick, were compared with normal arachnoidal cap cells and meningiomas.
  • The immunoprofile was similar to normal cap cells with one exception; whereas normal cells were uniformly negative for PR, nuclear positivity was seen in 64% of hyperplasias, a frequency similar to that of benign meningiomas.
  • Our data suggest that meningothelial hyperplasia is a reactive process that is usually distinguishable from meningioma based on clinicopathologic and genetic features.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Meningioma / genetics. Meningioma / metabolism. Meningioma / pathology. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912882.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS41520
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


87. Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R: Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2. Clin Neurol Neurosurg; 2009 Jun;111(5):454-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2.
  • In general, patients present bilateral vestibular schwannomas, meningiomas and neurinomas of the central and peripheral nervous system as well as neurofibromas and gliomas.
  • There is no reported case of pulmonary meningiomas and neurinomas associated with NF2 until now.
  • RESULTS: The reported patient presented a de novo NF2 germline mutation (R341X) and displayed the Wishart-type of NF-2 since she is 11 years old, with a huge anaplastic biparietal falx meningioma and a tentorium meningioma and a tumour-associated parietal mass as well as hypacusis starting at the infant age of 3 years.
  • Moreover, recurrent pulmonary tumours developed and were classified as benign meningiomas and a single neurinoma.
  • CONCLUSION: This rare case extends our knowledge of NF2 and also raises interesting questions about the pathogenesis of meningiomas outside the CNS.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary. Neurofibromatosis 2 / complications


88. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102 Suppl:134-9
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyst formation following gamma knife surgery for intracranial meningioma.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • METHODS: The medical records of 160 patients with 184 tumors were examined for those with follow-up data of more than 2 years among 270 patients who underwent GKS for intracranial meningiomas between February 1992 and November 2001.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / surgery. Cysts / etiology. Cysts / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications. Radiosurgery / instrumentation

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662796.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Couldwell WT, Cole CD, Al-Mefty O: Patterns of skull base meningioma progression after failed radiosurgery. J Neurosurg; 2007 Jan;106(1):30-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of skull base meningioma progression after failed radiosurgery.
  • OBJECT: Stereotactic radiosurgery has been reported to be an effective alternative to surgical removal of small to medium benign meningiomas as well as an adjuvant treatment modality to reduce the risk of tumor progression after subtotal resection.
  • Little is known, however, regarding the growth patterns of meningiomas that fail to stabilize after radiosurgery.
  • METHODS: The authors report 13 cases of benign skull base meningiomas (World Health Organization Grade I) that demonstrated progression after radiosurgical treatment as a primary or an adjuvant therapy.
  • CONCLUSIONS: Skull base meningioma growth can be aggressive after failed radiosurgery in some patients, and treatment failure can occur at long intervals following treatment.
  • Special attention must be devoted to such significant occurrences given the increasing number of patients undergoing stereotactic radiosurgery for benign tumors, and careful extended (> 10 years) follow up must be undertaken in all patients after radiosurgery.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236485.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Yue Q, Isobe T, Shibata Y, Anno I, Kawamura H, Yamamoto Y, Takano S, Matsumura A: New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol; 2008 Dec;18(12):2901-11
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma.
  • This study was aimed to clarify some ambiguities in the interpretation of proton magnetic resonance spectroscopy (1H-MRS) of meningiomas.
  • The cases of 31 meningioma patients (27 benign and 4 nonbenign meningiomas) that underwent single-voxel 1H-MRS (PRESS sequence, TR/TE = 2,000 ms/68, 136, 272 ms) were retrospectively analyzed.
  • All meningiomas demonstrated increased choline and decreased creatine, except for a lipomatous meningioma that only displayed a prominent lipid (Lip) peak.
  • Alanine (Ala) and lactate (Lac) coexisted in eight cases, indicating an alternative pathway of energy metabolism in meningiomas.
  • Glutamine/glutamate (Glx) was helpful for the recognition of meningioma when Ala was absent.
  • N-acetyl compounds(NACs) were observed in nine cases whose voxels were completely limited within the tumors, indicating that meningiomas might have endogenous NACs.
  • Lac was indicative of an aggressive meningioma, although not always a nonbenign one.
  • Lip not only represented micronecrosis in nonbenign meningiomas, but also reflected microcystic changes or fatty degeneration in benign meningiomas.
  • 1H-MRS reflects some distinctive biochemical and pathological changes of meningiomas that might be misinterpreted.
  • [MeSH-major] Biomarkers, Tumor / analysis. Choline / analysis. Creatine / analysis. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641997.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


91. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • Malignant meningiomas are associated with less than 2 years median survival.
  • The inability to predict recurrence and progression of meningiomas induces significant anxiety for patients and limits physicians in implementing prophylactic treatment approaches.
  • Five recurrent and progressive meningiomas for which surgical specimens were available from the original and progressed grades were selected and tested against nonprogressive high-grade meningiomas, high-grade gliomas, and nontumor brain specimens.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down


92. Rao S, Sadiya N, Doraiswami S, Prathiba D: Characterization of morphologically benign biologically aggressive meningiomas. Neurol India; 2009 Nov-Dec;57(6):744-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of morphologically benign biologically aggressive meningiomas.
  • BACKGROUND: Meningiomas are presently categorized into three grades by World Health Organization (WHO).
  • Grade I, in general, is expected to behave in a benign fashion.
  • However, a borderline group of grade I meningioma also exists, which may behave aggressively.
  • AIMS AND OBJECTIVE: To evaluate the proliferation index and p53 antigen expression of meningiomas and correlate with histological grade and clinical course.
  • MATERIALS AND METHODS: All 123 cases of meningiomas, diagnosed between January 2000 and August 2007, were regraded according to WHO 2000 criteria.
  • Mean Ki-67 labeling index (Ki-67 LI) was 3.8%, 13.7%, 19.4% for grade I, II, and III cases, respectively.
  • Mean p53 expression was found to be 15.5%, 57%, 60.8%, and 62.5% for grade I, II, III, and recurrent cases, respectively.
  • All recurrent cases were histologically WHO grade I, and showed a high Ki-67 LI and p53 expression with mean Ki-67 LI and p53 expression of 8.6% and 62.5% respectively.
  • CONCLUSION: Utilization of markers for proliferation and cell cycle regulators in combination with histopathological features helps in the identification of a subset of biologically aggressive morphologically benign meningiomas.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139503.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


93. Grujicić M, Vucković N, Vuleković P: [Morphological characteristics of meningiomas]. Med Pregl; 2010 Mar-Apr;63(3-4):237-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological characteristics of meningiomas].
  • INTRODUCTION: Meningiomas are common intracranial neoplasms which originate from the soft meninges, precisely from meningeal arachnoidal cells.
  • The aim of this investigation was to establish the age and sex distribution of the examinees, localization, frequency and histological types of meningiomas.
  • Out of 490 patients with diagnosed intracranial tumors, 137 (27.96%) were diagnosed to have meningiomas.
  • RESULTS: Meningiomas were more frequent in females (63%) than in males (37%) and they were most common in the 50-59 year age group (37.2%).
  • The most common localization of meningiomas was the frontal region (36.5%).
  • Meningiomas were more common on the left side (44.5%).
  • In regard to other histological types of intracranial tumors, meningiomas were more frequent in females (36.3%).
  • The most common histological type of meningiomas was transitional meningiomas (59.1%).
  • The commonest histological types of meningiomas were benign meningiomas (93.4%).
  • Malignant histological types of meningiomas were more common in males (83.3%), whereas benign histological types were more common in females (64.1%).
  • CONCLUSION: A typical patient with meningiomas is a woman 50-59 years old.
  • On histology it is benign, transitional type of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053467.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


94. Tlachacova D, Schmitt M, Novotny J Jr, Novotny J, Majali M, Liscak R: A comparison of the gamma knife model C and the Automatic Positioning System with Leksell model B. J Neurosurg; 2005 Jan;102(s_supplement):25-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data were analyzed in patients in whom the following diagnoses had been made: vestibular schwannoma, pituitary adenoma, meningioma, solitary metastasis, and other benign and malignant solitary tumors.
  • CONCLUSIONS: With the C model there was a better conformity for most treated targets, such as vestibular schwannomas (p = 0.005) and meningiomas (p = 0.015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306471.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; conformity index / extracranial exposure / staff exposure / stereotactic radiosurgery
  •  go-up   go-down


95. Aghi MK, Eskandar EN, Carter BS, Curry WT Jr, Barker FG 2nd: Increased prevalence of obesity and obesity-related postoperative complications in male patients with meningiomas. Neurosurgery; 2007 Oct;61(4):754-60; discussion 760-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of obesity and obesity-related postoperative complications in male patients with meningiomas.
  • OBJECTIVE: The female preponderance of meningiomas may reflect hormonal influences on meningioma growth.
  • We hypothesized that because obesity affects male steroid hormone synthesis, male patients with meningiomas might exhibit a high obesity rate, which, in turn, might increase their frequency of postoperative complications.
  • METHODS: We retrospectively reviewed male patients who underwent craniotomy for benign meningiomas at our institution between 2001 and 2005 (n = 32) and used male patients undergoing craniotomy for aneurysms (n = 32) or glioblastomas (n = 32) from 2001 to 2005 as control subjects.
  • RESULTS: Male patients with meningiomas had a higher average BMI (30.2 kg/m) than male patients with aneurysms (BMI = 27.5 kg/m) or gliomas (BMI = 25.9 kg/m) (P = 0.04).
  • The obesity rate in men with meningiomas (47%) exceeded that in men with aneurysms (19%) or gliomas (3%) (P = 0.2).
  • The median age-normalized BMI percentile was greater in men with meningiomas (67 th percentile) than in men with aneurysms (49th percentile) or gliomas (52 nd percentile) (P = 0.02).
  • Deep vein thrombosis/pulmonary embolus was more common in men with meningiomas (19%) than in men with aneurysms (0%) or gliomas (3%) (P = 0.002).
  • Wound infections were more common in men with meningiomas (6%) than in men with aneurysms (3%) or gliomas (0%) (P = 0.2).
  • The 53% of obese patients with meningiomas who were readmitted with postoperative complications exceeded the 18% of nonobese patients with meningiomas who were readmitted (P = 0.03); complications included deep vein thrombosis and pulmonary embolus (27 and 12%, respectively, in obese and nonobese patients with meningiomas) and postoperative fever (53 and 35%, respectively, in obese and nonobese patients with meningiomas).
  • CONCLUSION: We found that many men with meningiomas are obese, suggesting a hormonal influence on meningiomas in men as well as women.
  • Our results also underscore the high risk of postoperative complications in obese male patients with meningiomas.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Obesity / epidemiology. Postoperative Complications / epidemiology

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986936.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS; 2009 Sep;117(9):651-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
  • Meningioma is a common neoplasm that constitutes almost 30% of all primary central nervous system tumors and is associated with inconsistent clinical outcomes.
  • The extracellular matrix proteins play a crucial role in meningioma cell biology and are important in tumor cell invasion and in progression to malignancy.
  • The aim of this study was to evaluate the expression of SPARC with proliferation index, p53 reactivity in WHO grade 1 (benign), grade 2 (atypical) and grade 3 (anaplastic) meningiomas and correlate with clinical features of the patients, including location of the tumor, recurrence of the tumor and survival of patients.
  • We studied 111 meningiomas, 69 being benign, 34 being atypical and eight being anaplastic meningiomas of various histological types.
  • Using immunohistochemical analysis, we evaluated the expression of SPARC, Ki-67 (MIB-1) and p53 in meningiomas.
  • A high immunohistochemical score (4-6) for SPARC was more frequent in atypical and in anaplastic meningiomas than in benign meningiomas (p < 0.01).
  • MIB-1 proliferation index showed significant association between tumor grades in meningiomas (p < 0.01).
  • The immunoreactivity of p53 protein and MIB-1 score were significantly higher in recurrent meningiomas than in non-recurrent meningiomas.
  • The high SPARC expression scores were predominantly identified in meningothelial, fibrous and chordoid meningiomas; low SPARC expression scores were mostly spotted in secretory and psammomatous meningiomas.
  • Evaluating SPARC expression might help assessing recurrence risk and survival estimation in meningiomas.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Osteonectin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703125.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Osteonectin; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


97. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas.
  • The application of this technique for resection of meningiomas has barely been explored.
  • The aim of this study was to evaluate the utility of 5-ALA-induced fluorescence as a visual tool in meningioma resection and its correlation with histological findings.
  • METHODS: A total of 33 consecutive patients undergoing resection of intracranial meningiomas from December 2007 to August 2009 were included in this study.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • In 1 (3%) patient, histological anaplastic signs (WHO III) could be demonstrated.
  • The fluorescence did not correlate with the histological findings (n = 30 WHO I-II, n = 1 WHO grade III) or with preoperative brain edema and administration of steroids.
  • CONCLUSIONS: 5-ALA-induced fluorescence is a useful and promising intraoperative tool for the visualization of meningioma tissue.
  • The novel findings demonstrated in this study in terms of high fluorescence and poor correlation with histological findings highlight the usefulness of this technique as a routine visual tool to achieve optimal resection of meningiomas.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


98. Maes L, Lippens E, Kalala JP, de Ridder L: The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif; 2005 Feb;38(1):3-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas.
  • Meningiomas are considered as benign neoplasms affecting the coverings of the central nervous system and compromise approximately 20% of all intracranial tumours.
  • The aim of this study is to evaluate the prognostic significance for recurrence of the human telomerase catalytic subunit (hTERT) in the cells of meningiomas.
  • Archival material from 29 non-recurrent and 32 recurrent tumours has been evaluated, including specimens from World Health Organization (WHO) stages I (n = 73), II (n = 2) and III (n = 12).
  • Although the tumours were categorized as benign meningiomas following the WHO classification, recurrence in 22 of 50 cases did not correlate with the tumour stage.
  • For hTERT staining, the following results were found for nucleolar and total nuclear staining, respectively: non-recurrent meningiomas, 2.9% (+/- 7.7) and 3.0% (+/- 8.0); recurrent meningiomas at first resection, 16.8% (+/- 19.7) and 31.6% (+/- 30.2).
  • Concerning the Ki-67 labelling index (LI): for the group of non-recurrent meningiomas, results were 2.1% (+/- 1.7) and for the recurrent group at first resection, 1.7% (+/- 2.0).
  • A significant difference was seen for the hTERT staining (P < 0.001) between the non-recurrent and recurrent meningiomas, whereas no statistical significance was found for Ki-67.
  • In conclusion hTERT-positive meningiomas had a high incidence for recurrence.
  • [MeSH-major] Antigens, Neoplasm. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Telomerase / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679862.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


99. Maiuri F, De Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E: Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol; 2007 Mar;82(1):63-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.
  • OBJECTIVE: Recurrence of apparently completely resected benign meningiomas is a rather frequent event, the mechanisms of which are still unclear.
  • The aim of this study is to define the pathological features, proliferation indexes, growth factors and hormone receptor expression in predicting the meningioma recurrence.
  • METHODS: Two groups of 50 completely resected benign WHO I meningiomas, with and without recurrence respectively, have been reviewed.
  • VEGF and EGF-R were not correlated with the recurrence of meningiomas, whereas the Bcl-2 protein positivity showed a tendency to the significativity (P=0.0294).
  • CONCLUSIONS: Higher MI and Ki-67 LI and PR negativity are predictive factors of recurrence of benign (WHO I) completely resected meningiomas, particularly when Bcl-2 positivity is associated.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Mitotic Index. Neoplasm Recurrence, Local / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225937.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Progesterone
  •  go-up   go-down


100. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg; 2007 Aug;107(2):325-36
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for benign meningioma.
  • OBJECT: Meningioma is the most frequent benign tumor treated with Gamma Knife surgery (GKS); however, the assessment of its efficacy and safety in slow-growing tumors is an ongoing process, requiring analysis of long-term results.
  • METHODS: Three hundred sixty-eight patients harboring 400 meningiomas treated between 1992 and 1999 at Na Homolce Hospital were evaluated.
  • CONCLUSIONS: Stereotactic radiosurgery is a safe method of treatment for meningiomas.
  • A minimum margin dose of 12 to 16 Gy seems to represent the therapeutic window for benign meningiomas with a high tumor control rate in a mid-term follow-up period.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695387.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement